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Background: Subglottic squamous cell carcinoma is a rare subsite of laryngeal cancer, 
which is believed to behave more aggressively and portend a worse prognosis than 
other laryngeal cancer subsites (supraglottis and glottis).  Our objective was to utilize a 
population-based cancer registry to report the overall survival and laryngectomy-free 
survival in patients diagnosed with subglottic squamous cell carcinoma, and to examine 
trends in outcomes over time. We also compared overall survival in patients treated with 
primary laryngectomy versus radiation. 
 
Methods: We carried out a retrospective population-based study of patients with a new 
diagnosis of squamous cell carcinoma in the province of Ontario, Canada over a 15-
year period (1995-2009). We identified patients with a new diagnosis of subglottic 
squamous cell carcinoma using the Ontario Cancer Registry. We determined 
demographics, comorbidity measures, staging, survival and primary treatment with 
laryngectomy using the linked population-based healthcare databases in Ontario. We 
first determined the overall survival and laryngectomy free survival of patients with 
subglottic cancer. In a secular trends study, we then examined the trends in overall 




Results: A total of 4927 cases of laryngeal carcinoma were identified, with 89 patients 
defined as primary subglottic carcinoma (1.8%). Among the subglottic cohort, 68 
(76.4%) were male, and the mean (25th, 75th percentile) age at diagnosis was 68 (60- 77 
years). The 5-year overall survival was 47.2%, while the 5-year laryngectomy-free 
survival was 31.5%. No differences were observed in overall survival (OS) or 
laryngectomy-free survival (LFS) across years over the 15-year study period (p=0.42 
OS, p=0.83 LFS).  Thirteen patients (15%) were treated with primary laryngectomy. 
Primary treatment with laryngectomy was not associated with a different risk of mortality 
compared with radiation.  
Conclusions: The overall survival and laryngectomy-free survival of patients with 
subglottic carcinoma is poor and has remained stable over time (1995-2009).  Primary 









Summary for Lay Audience 
Cancer that occurs below the level of the vocal cords, also known as subglottic cancer, 
is very rare. Subglottic cancer is thought to lead to a higher chance of death than cancer 
that occurs in the vocal cords or above the vocal cords, but we don’t know for sure 
because it is so rare. Our goal with this study was to use a large database of patients 
with subglottic cancer to determine if it does have a higher chance of death than other 
vocal cord cancers and whether treatment with surgery or radiation is better.  We looked 
at all patients in Ontario from 1995-2009 who were diagnosed with subglottic cancer. 
We searched the database for other factors that might contribute to the survival of 
patients with subglottic caner and impact their chance of cure. We used the data to 
determine how many patients were still alive at 5 years after a diagnosis of subglottic 
cancer and how many patients were still alive at 5 years and still retained their voice 
box (that is, they did not have to have it removed to cure the cancer).  
In total we found 89 patients who had subglottic cancer in Ontario during our study 
period. At 5 years, 47.2% of patients were still alive and 31.5% of patients will still alive 
and still had their voice box. Over the 15 years of our study, we did not find that the 
chance of survival from subglottic cancer changed. Fifteen percent of patients were 
treated with surgery and the rest were treated with radiation. We found that the 
treatment chosen did not impact survival from subglottic cancer.  
Patients with subglottic cancer have a lower chance of survival than patients with 
cancer in the vocal cords or above the vocal cords, and survival has not changed over 
the study timeframe 1995-2009. The treatment chosen for subglottic cancer does not 
iv 
 
appear to impact survival at 5 years. More research is needed to improve the overall 
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CHAPTER ONE: OVERVIEW OF THESIS AND INTRODUCTION 
1.1 Introduction  
Squamous cell carcinoma (SCC) of the subglottis is rare, representing less than 5% of 
all laryngeal cancer.[1-3]  In the past, defining primary subglottic cancer versus glottic 
cancer with subglottic extension was challenging due to poor imaging and laryngoscopy 
equipment.[4]  The superior anatomic boundary of the subglottis has also been 
inconsistently defined, ranging from below the free edge of the true vocal cord to 5mm 
below the vocal cord to 1cm below the lateral margin of the ventricle, further 
complicating accurate classification of this disease subsite.[5]  The rarity of the disease, 
the historic difficulty in defining primary versus secondary subglottic cancer as well as 
the changing definition of the superior boundary have made reporting treatment and 
survival outcomes of this rare carcinoma challenging.  
Primary subglottic SCC is thought to herald a worse prognosis than the other subsites 
of laryngeal cancer secondary to advanced stage at presentation, propensity for 
paratracheal and upper mediastinal lymphatic spread, and the increased risk of stomal 
recurrence.[6-9] Historically, total laryngectomy has been employed as the standard of 
care for the treatment of subglottic carcinoma.[4]  Laryngectomy involves removal of the 
entire larynx (voice box) and for most patients this surgical procedure results in a 
significant decline in their quality of life. Recent retrospective studies have 
demonstrated comparable survival outcomes for patients treated with primary 
radiotherapy.[10, 11] Most published reports on patients with subglottic carcinoma are 





studies[10, 18]. Only one published study reports on the outcome of laryngectomy-free 
survival.[12, 18-20] Most of these studies are also limited by institutional selection bias, 
and incomplete reporting of surgical data.[12, 18-20] Laryngectomy-free survival is an 
important outcome to report as the reason most patients pursue radiation is to preserve 
their larynx. We conducted a population-based study to determine the outcomes of 
patients with subglottic carcinoma and the secular trends in survival over time. Using 
the linked population-based databases in Ontario, we can determine the laryngectomy-
free survival of this patient population following treatment with primary radiation. We 
were also able to compare the survival outcomes of patients treated primarily with 
surgery and radiation.  
 
1.2 Thesis Overview 
The thesis is structured into the following chapters: 2. Introduction to Laryngeal Cancer; 
3. Literature Review of Subglottic Cancer; 4. Rationale and Research Approach; 5. 
Objectives and Hypothesis; 6. Patients and Methods; 7. Results; and 8. Discussion. In 
Chapter 2 we provide an overview of laryngeal cancer workup and epidemiology. We 
then describe the current treatment options for laryngeal cancer and discuss the 
prognosis and survival outcomes for laryngeal cancer highlighting a knowledge gap of 
reporting of survival outcomes with adequate sample size. In Chapter 3, we perform a 
scoping review of the literature on subglottic carcinoma to improve our understanding of 
subglottic squamous cell carcinoma, including the survival outcomes. We synthesize the 





studies. In Chapter 4, we state the rationale for our research approach. In Chapter 5 we 
provide our objectives and hypothesis. In Chapter 6 we describe our methods including 
the databases used, definition of outcomes and statistical methodology. Chapter 7 
describes our results and in chapter 8 we discuss our findings and their implications. 
Finally, we conclude with a discussion of the strengths and weaknesses of this work 







CHAPTER 2: INTRODUCTION TO LARYNGEAL CANCER, TREATMENT AND 
OUTCOMES 
2.1 Introduction  
The larynx has three main functions: swallowing; speech; and respiration. It is 
responsible for protecting the airway, vocalization and protecting the lungs. With 
swallowing the larynx elevates and it is able to generate pressure with glottic closure 
which is important for straining and gastrointestinal function. Cancers of the larynx can 
impact all three physiologic functions to varying degrees. Worldwide, laryngeal cancer is 
the second most common head and neck cancer and it has an incidence of 157,000 
new cases each year.[21] In the following sections we provide an overview of laryngeal 
cancer, including anatomy, epidemiology, histology, clinical evaluation, staging, 
treatment and survival outcomes.  
 
2.2 Anatomy of the larynx 
The larynx is composed of cartilage, ligaments, membranes and intrinsic and extrinsic 
laryngeal muscles. It contains three cartilaginous structures, which include the paired 
arytenoid, cuneiform and corniculate cartilages and three unpaired cartilaginous 
structures, the thyroid, cricoid and epiglottis.  
 
Blood supply to the larynx is provided by the superior and inferior laryngeal arteries. The 
superior laryngeal artery, which arises from the superior thyroid artery, provides blood 





laryngeal artery, a branch of the inferior thyroid artery. Nervous innervation of the larynx 
is supplied by the superior laryngeal nerve and the recurrent laryngeal nerve. The 
superior laryngeal nerve provides sensation above the vocal folds and motor innervation 
to the cricothyroid muscle. The recurrent laryngeal nerve supplies both sensory and 
motor innervation to the glottis and below and the remaining of the laryngeal muscles.  
 
The larynx is divided into three subsites, the supraglottis, glottis and subglottis. These 
anatomic subsites are based on embryologic development which results in clinically 
important difference between the subsites. The supraglottis is composed of the 
epiglottis, aryepiglottic folds, arytenoids and false cords. The supraglottis spans from 
the epiglottis to the laryngeal ventricle. The glottis is composed of the true vocal cords, 
anterior commissure, interarytenoid region and floor of the ventricle. The glottis extends 
inferiorly to 1cm below the apex of the ventricles. The subglottis starts 1 cm below the 
apex of the ventricle and extends to the inferior border of the cricoid cartilage. The 
border that divides the glottis from the subglottis has been inconsistently defined 
however, and this will be discussed in subsequent sections.  
 
Due to the differences in embryologic development, the different subsites of the larynx 
have different patterns of lymphatic drainage. The supraglottis drains into bilateral 
lateral neck lymph node basins. Given the rich lymphatic drainage of the supraglottis, 
even early stage supraglottic cancers have a high propensity for lymphatic involvement. 
Clinically this results in a high incidence of unilateral or bilateral metastases (25-75% for 





node involvement usually only occurs with advanced stage disease, and is more likely 
to be unilateral. Subglottic lymphatic drainage is most commonly to the central 
compartment lymph nodes.  
 
The larynx is also composed of laryngeal membranes and spaces which clinically 
impact the spread of disease and treatment. These membranes (conus elasticus, 
quadrangular membrane and thyrohyoid membrane) provide anatomic barriers to 
spread of cancer which result in cancer spreading predictably through spaces that 
provide the least resistance. Two important spaces in the larynx are the preepiglottic 
space and the paraglottic space. Both spaces are rich with lymphatics and blood 
vessels and continuous with each other allowing spread between compartments.   
 
Table 1 describes the subsites of the larynx and the regions of each subsite. The 
supraglottis extends from the tip of the epiglottis superiorly to the laryngeal ventricle. 
The laryngeal ventricle is a space bounded above by the false vocal cords and below by 
the true vocal cords. The subsites of the supraglottis are listed in Table 1. Depending of 
the subsite of the supraglottis that is involved there may or may not be anatomic 
barriers that prevent spread of cancer to other sites.  
 
The glottic larynx encompasses the floor of the ventricle, the true vocal folds and 
extends to 1 cm below the free edge of the cord and the anterior commissure. As 





remain localized for longer periods of time. In addition, the thyroid cartilage prevents 
many early stage cancers in the submucosa from spreading.  
 
The subglottis begins at the inferior limit of the glottis and extends to the inferior edge of 
the cricoid cartilage. The laryngeal subglottis is contained by the cricoid cartilage and 
the conus elasticus. Spread of malignant tumors beyond the boundaries of the 
subglottis is easily accomplished through the cricothyroid membrane anteriorly and 
laterally, and into the hypopharynx posteriorly.[9] Cancers arising in the subglottis have 
been known to have a unique circumferential pattern of intraluminal spread, with up to 
half of tumors involving a complete ring and over 90% involving at least two thirds of the 
circumference.[23] As a result subglottic cancers have a propensity for extralaryngeal 
extension.   
 
Glottic cancers can spread from the glottis to the subglottis making the distinction 
between glottic tumors with secondary subglottic spread and primary subglottic tumors 
difficult.[6] In subglottic tumors the spread of the tumor is thought to be circumferential 
and inferior with superior spread less common.[24]  Some have suggested that if the 
tumor grows into multiple regions, the region with the highest tumor volume is defined 
as the origin.   
 
Table 1 Anatomic region and subsites of the larynx 
Region of Larynx Subsites 
















2.3 Epidemiology of Laryngeal Cancer 
Laryngeal carcinoma is the second most common malignancy of the head and neck and 
the eleventh most common form of cancer worldwide, comprising 1.1% of all new 
cancers.[25]  Laryngeal cancer occurs more frequently with advancing age and among 
men.[26] The median age of diagnosis for patients with laryngeal cancer is 65 years and 
the median age at death is 68 years.[26] Men are more prone to the disease, with a 
0.6% lifetime probability of developing laryngeal cancer, whereas for women the figure 
is significantly lower (0.1%).[27] Cancer incidence varies across geographical regions. 
In developing countries, the age-adjusted incidence in 2012 was 3.5 per 100000, 
compared to an incidence of 5.1 in more developed countries.[25] In Canada, the age-
standardized incidence rates of laryngeal cancer has declined over the last decades in 
men from the 1988 high point of 11.6 per 100000 to 5.1 in 2017. A decrease in females 
was also observed, from 2.0 to 0.8.[27] 
 





Ninety-five percent of laryngeal malignancies are squamous cell carcinomas (SCCs) 
arising from the stratified squamous epithelial lining of the larynx.[28, 29] Other 
laryngeal cancer pathologies include verrucous carcinoma, spindle cell carcinoma, 
glandular carcinomas (adenocarcinoma not otherwise specified (NOS), adenoid cystic, 
mucoepidermoid) [30-32], sarcomas (chondrosarcoma, fibrosarcoma and liposarcoma) 
[33], neuroendocrine tumors and metastatic disease.[22] Forty percent of laryngeal 
cancers will be diagnosed at an advanced stage (III or IV).[34] The glottis (51%) is the 
most common site for laryngeal cancer followed by the supraglottis (32%) and subglottis 
(2%).[35] In Ontario, population-based data has demonstrated that glottic cancers 
represent 64.8% of all laryngeal cancer diagnosed from 1995-2007, while supraglottic 
account for 28.2% and subglottic 1.8% of laryngeal cancer.[36]  
 
There are a variety of histologic subtypes of laryngeal SCCs that have been shown to 
impact prognosis. Basaloid laryngeal SCC have characteristic “blue cells” on histology, 
they are more likely to be confused with other tumors and are associated with a poorer 
prognosis than typical laryngeal SCCs in most reports.[37] Verrucous carcinoma is a 
rare variant of SCC. It has an exophytic warty appearance and may be confused with 
squamous papilloma on clinical examination.[38] Although generally a less aggressive 
variant, Verrucous carcinoma is generally less aggressive than traditional SCC but is 
may contain small nests of traditional aggressive SCC. These tumors may be resistant 
to radiation, so surgical resection is generally preferred.[39] Papillary variant laryngeal 
SCC has an exophytic appearance, and a papillary-type growth pattern. These tumors 





good prognosis compared to traditional SCC. Local control and survival are excellent 
regardless of which treatment is chosen.[40, 41] Spindle cell variant is rare but can 
often be confused on histology with sarcoma, malignant melanoma and other malignant 
or benign spindle proliferations.[22] Survival rates are like traditional laryngeal SCC but 
they are locally aggressive.[42] Adenosquamous variant is another rare variant and it is 
challenging to differentiate them from salivary gland malignancies. On histology the 
characteristics are pseudoglandular structures and cystic degeneration. They are 
aggressive tumors and are associated with a poor prognosis.[43] 
 
2.5 Risk Factors for laryngeal cancer 
2.5.1  Tobacco and alcohol 
 The vast majority (85%) of laryngeal cancers can be attributed to tobacco and 
alcohol use.[44, 45] Compared with nonsmokers, current smokers have a 10- to 20- fold 
increased risk of laryngeal cancer.[46, 47] In addition to being a risk factor for the 
development of laryngeal cancer, smoking has also been identified as an independent 
risk factor for local recurrence and for recurrence at an earlier point than those who 
stopped smoking.[47] While the predominant risk factor for larynx cancer is smoking, 
alcohol is also an independent and synergistic risk factor.[44, 45]  
2.5.2 Human Papillomavirus 
 Given that human papillomavirus (HPV) is associated with the majority cancer of 
the oropharynx, it was initially thought that HPV did not play a role in laryngeal cancer. 
However, new research is emerging that demonstrates the presence of HPV and/or the 





demonstrated that laryngeal HPV-positive tumours may be associated with improved 
overall survival.[48] It is estimated that the prevalence of HPV ranges from 20% to 30% 
in laryngeal cancer; however, this percentage varies widely between studies and 
depends on the detection method used.[49, 50] More work is needed to determine the 
clinical relevance of HPV/p16-positive status in laryngeal cancer, as this remains 
controversial.[51-53]  
2.5.3  Other risk factors 
 Other risk factors include carcinogens in the workplace such as asbestos, nickel 
compounds, wood dust, leather products, paint, diesel fume, textile dust, and glass-
wool.[54-56] Dietary factors have also been noted, with red meat increasing the risk of 
laryngeal cancer, while a diet varied in fruit and vegetables potentially has a protective 
effect.[57, 58] In addition, the role that both gastroesophageal and laryngopharyngeal 
reflux play in the disease process is still controversial and under investigation.[59, 60] 
To date, only an association between tobacco and alcohol exposure and risk of 
laryngeal cancer has been established.  
 
2. 6  Clinical Presentation and Diagnostic Workup 
2.6.1 History and Physical Examination 
Laryngeal cancer patients typically present with symptoms of hoarseness, voice 
changes, the sensation of something stuck in the throat, and discomfort in the throat. As 
the tumor grows, more severe symptoms including dyspnea (difficulty breathing), 
dysphagia (problems swallowing), odynophagia (pain with swallowing), hemoptysis 





can vary based on the site of the larynx where the cancer is located (glottis, supraglottis 
or subglottis) and stage at presentation. Tumors of the glottic region typically present 
with hoarseness, referred ear pain (otalgia), dysphagia, chronic cough, stridor (noisy 
breathing) and hemoptysis.  Whereas supraglottic tumors typically present with 
pressure symptoms such as lump in the throat or throat pain and a neck mass from 
cervical metastasis. Due to the early presentation of hoarseness, glottic tumors are 
generally detected at an earlier stage than supraglottic tumors.[28, 61, 62] Subglottic 
carcinoma may present with stridor and dyspnea on exertion. However, there are few 
early symptoms and most subglottic cancers present at an advanced stage.[6] It is 
important to assess the patient’s comorbidities, and functional status. Particular 
attention should be placed on the patient’s respiratory function, as this must be 
considered when determining the options for treatment. 
 
When a patient presents in the outpatient clinic with a suspected laryngeal tumor, the 
assessment includes clinical examination as well as fiberoptic laryngoscopy 
investigation. Complete head and neck examination is important for identifying second 
primary malignancies, assessing dentition, identifying lymphadenopathy and 
determining nutritional status. Fiberoptic laryngoscopic examination allows for 
evaluation of the dynamic function of the larynx, such as the patency of the airway, the 
mobility of the vocal cords.  This allows for determination of the extent of the tumor and 
accurate staging. Videolaryngoscopy with stroboscopy may also be performed to obtain 
information of the function and vibrating properties of the affected vocal cord and as a 






2.6.2 Examination under general anesthesia 
After clinical examination, the patient is consented for a general anesthetic where the 
tumor can be biopsied and assessed in more detail. Direct laryngoscopy also allows for 
palpation of the tumor and laryngeal structures. During the general anesthesia biopsies 
are taken for confirmation of the cancer diagnosis. The biopsies are examined by a 
pathologist to confirm cancer diagnosis. During the anesthetic the pharynx, larynx, 
hypopharynx and esophagus are carefully examined to rule out secondary primary 
tumors as well to allow for a better assessment of the extent of the tumor. 
 
2.6.3 Diagnostic Imaging 
Imaging of laryngeal tumors is helpful in determining the extent of disease including 
revealing regional (cervical) and distant (lung and liver) metastatic disease, cartilage 
invasion and extension to the laryngeal spaces. Patients should undergo diagnostic 
structural imaging, a CT or an MRI with contrast to determine the presence or absence 
of cervical lymph nodes, distant metastatic disease, cartilage invasion, preepiglottic or 
paraglottic space invasion and extralaryngeal spread as part of their initial stating 
workup. Both a CT and MRI are appropriate initial imaging modalities for the neck. A CT 
is useful in the assessment of submucosal disease, extralaryngeal extension, as well as 
cervical metastasis. CT can be particularly helpful in the detection of cartilage 
invasion.[63]  CT may however overestimate cartilage invasion leading to overstaging of 





to preepiglottic and paraglottic space. Both CT and MRI have an 87-93% accuracy in 
staging the neck.[65] 
 
The most common sites of distant metastasis for laryngeal cancer are the lungs 
followed by the liver. A screening CT chest should be done to screen for lung 
metastasis or synchronous primary lung lesions especially in smokers. Abdominal CT or 
liver ultrasonography can also be done if there is increased suspicion. A PET/CT is 
helpful in detecting subtle metabolically active lesions/nodes and has been shown to 
change cancer management in 18-31% of cases.[66] 
 
2.6.4 Additional tests and consultations 
All patients should undergo routine pretreatment laboratory tests to assess for signs of 
metastatic disease, thyroid function and nutritional status.[65] Assessment by a 
multidisciplinary team is important in caring for patients with laryngeal cancer. The 
multidisciplinary team should include head and neck surgery, medical oncology, 
radiation oncology, dentistry, speech pathology, nutrition and social work. Each member 
of the multidisciplinary team will address specific needs of patients diagnosed with 
laryngeal cancer.  
 
2.7 Staging of Laryngeal Cancer 
The eighth edition of the AJCC TNM staging protocol, is currently in use (Tables 2 and 
3).[67] Laryngeal cancer is staged according to the tumor, node, metastasis (TNM) 





physical examination, endoscopic evaluation and imaging. Accurate staging is essential 
in planning and assessing the appropriate treatment modalities and requirement for 
adjuvant therapy. 
 
Table 2 TNM Staging for Laryngeal Cancer (AJCC 8th edition)[67] 
Tis Carcinoma in situ 
T1 Supraglottis: tumor limited to one subsite of supraglottis with normal cord 
mobility 
 Glottis:  
T1a, tumor limited to one vocal cord  
T1b, tumor limited to both vocal cords with normal vocal cord mobility 
 Subglottis: tumor limited to subglottis 
T2 Supraglottis: tumor invades mucosa of more than one adjacent subsite of 
supraglottis subsite or glottis or region outside supraglottis (eg, mucosa 
of base of tongue, vallecula, medial wall of pyriform sinus) without 
fixation of the larynx 
 Glottis: tumor extends to supraglottis and/or subglottis and/or with 





 Subglottis: tumor extends to vocal cord(s) with normal or impaired cord 
mobility 
T3 Supraglottis: tumor limited to larynx with cord fixation and/or invades any 
of the following: postcricoid area, preepiglottic space, paraglottic space, 
and/or inner cortex of thyroid cartilage 
 Glottis: tumor limited to the larynx with vocal cord fixation and/or invasion 
of paraglottic space and/or inner cortex of thyroid cartilage 
 Subglottis: tumor limited to larynx with vocal cord fixation and/or inner 
cortex of the thyroid cartilage 
T4 T4a, Moderately advanced local disease: tumor invades through the 
cricoid or outer cortex of the thyroid cartilage and/or invades tissues 
beyond the larynx (eg, trachea, soft tissues of the neck including deep 
extrinsic muscle of the tongue, strap muscles, thyroid or esophagus) 
 T4b, Very advanced disease: tumor invades prevertebral space, encases 
carotid artery, or invades mediastinal structures 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral node, 3cm or smaller in greatest 





N2 A, Metastasis in a single ipsilateral lymph node, larger than 3 cm but not 
larger than 6 cm in greatest dimension and ENE (-) 
 B, Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm 
in greatest dimension and ENE (-) 
 C, Metastases in bilateral or contralateral lymph nodes, none larger than 
6 cm in greatest dimension and ENE(-) 
N3 A, Metastasis in a lymph node, larger than 6 cmn in greatest dimension 
and ENE(-) 
B, Metastasis in any lymph node(s) with clinically overt ENE(+) 
M0 No distant metastasis 
M1 Distant metastasis 
 
Table 3 Prognostic Stage Groups for Laryngeal Cancer 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T1 N1 M0 
 T2 N1 M0 





Stage IVA T1 N2 M0 
 T2 N2 M0 
 T3 N2 M0 
 T4a N0, N1, N2 M0 
Stage IVB Any T N3 M0 
 T4B Any N M0 
Stage IVC Any T Any N M1 
 
Different from other malignant tumors, the TNM classification of laryngeal carcinoma 
includes a functional component, i.e. vocal cord mobility to differentiate between T1, T2 
and T3 laryngeal carcinoma. Vocal cord mobility is determined by flexible 
nasopharyngoscopy. Contrary to other head and neck tumors, the size of the tumor is 
not important for tumour staging. Rather, the involvement of adjacent structures impacts 
the tumour stage. Early stage laryngeal cancers are T1/T2 N0 (Stage I and II) and are 
characterized by small tumors with limited functional impact and minimal extension. 
These tumors are generally thought to require single modality treatment in the form of 
surgery alone or radiation alone. Advanced stage cancers T3/T4N1-3 are characterized 
by large tumors with significant impact on breathing, swallowing and speech. These 
tumors require multimodality treatment in the form of either primary surgery followed by 
radiation or primary treatment with a combination of chemotherapy and radiation.  
 





Treatment of laryngeal cancer depends on extent of the disease, baseline function of 
the patients, and the goal of preserving the patients’ speech and swallowing function. 
Generally, monotherapy with surgery or radiation (RT) is preferred for early stage 
tumors (Stage 1 and 2). With increasing tumor size, chemoradiotherapy (CRT) or 
radical surgery (laryngectomy-removal of the larynx) combined with postoperative RT or 
CRT may be recommended. Together, RT or CRT are termed “laryngeal preservation” 
protocols.  
 
Stage at presentation primarily determines the management of laryngeal cancer.  In 
addition, a variety of other factors are also influence the decision-making including the 
patient’s age, comorbidities, surgical access issues, the preferences of the treating 
multidisciplinary team and importantly, the desires of the patient.  
 
For Stage 1 and 2 cancers, the options for treatment include radiotherapy or transoral 
laser microsurgery (TLM). For a small number of patients there is the option of open 
partial laryngeal surgery. This is now undertaken infrequently following the introduction 
of TLM. It should be noted that there have been no randomized trials comparing the 
efficacy of the two main treatment modalities, radiotherapy and TLM. However, several 
cohort studies demonstrate similar cure rates for early stage laryngeal cancer with the 






The main options for the treatment of advanced laryngeal cancer currently are total 
laryngectomy or chemoradiotherapy. Other options used less commonly include partial 
open laryngectomy, near total laryngectomy and TLM (for select cases only).  
 
 
2.8.1 Radiotherapy for Laryngeal Cancer 
Radiotherapy or chemoradiotherapy can yield comparable results with surgery in the 
treatment of subglottic carcinoma. Early-stage cases can be treated with radiation fields 
directed at the larynx with a 1 to 2 cm margin. Radiation fields for advanced-stage 
cases usually include the larynx, bilateral cervical, supraclavicular and upper 
mediastinal lymph nodes. Total dose ranges between 50 and 75 Gy.[71] 
 
The main advantage of radiotherapy is that it can be administered to patients who are 
poor surgical candidates. Radiotherapy is also thought to have better voice outcomes. 
This hypothesis is based on the principle that the laryngeal structures are being 
“preserved”. This does not apply, however, if the laryngeal structures have already been 
destroyed by the malignant process. In addition, radiotherapy is a radical treatment so it 
can have a deleterious effect on the laryngeal structures especially in the long-term. To 
date, definitive comparison of voice outcomes between the two treatment methods has 
not been performed. However, an observational study has shown that quality of life 
outcomes for the two modalities appear to be similar.[72] Radiation is considered 






Adjuvant radiation is considered postoperatively for advanced laryngeal cancer, positive 
or close surgical margins after surgical resection, positive node metastases, and 
perineural or lymphovascular invasion. Radiotherapy is ideally started within 6 weeks of 
surgery. Radiation can sometimes be used for palliative treatment of unresectable 
cancers.  
 
Chemoradiation organ preservation strategies are used for advanced stage laryngeal 
cancer and have demonstrated that some larynges can be saved without compromising 
overall survival. In 1991, the Department of Veterans Affairs Laryngeal Cancer Study 
Group investigated whether induction chemotherapy and definitive radiation therapy 
with total laryngectomy (TL) reserved for salvage represented a better initial treatment 
approach for patients with advanced laryngeal cancer than TL with post-operative 
radiation therapy.[73] The conclusion was that induction chemotherapy and definitive 
radiation therapy can be effective in preserving the larynx in a high percentage of 
patients without compromising overall survival.[73]  
 
In 2003, a randomized trial RTOG-9111 was published on concurrent 
chemoradiotherapy for laryngeal preservation.[74] This trial was updated at the 2006 
American Society of Clinical Oncology annual meeting, and the findings confirmed the 
previous results: the 5-year laryngeal preservation rate was significantly better with 
concurrent chemoradiotherapy (83.6%) compared with induction chemotherapy (70.5%) 
or radiotherapy (RT) along (65.7%), without differences recorded in overall or disease-






In addition,  results of the “Meta-Analysis of Chemotherapy in Head and Neck Cancer” 
showed that concurrent chemoradiotherapy results in a significant 8% benefit in 5-year 
survival compared with RT alone, whereas adjuvant and induction chemotherapy did 
not improved survival.[76] Consequently, concurrent chemoradiotherapy appeared to be 
the most reasonable approach to preserve the larynx in patients with advanced 
laryngeal cancer. The current standard of care is definitive chemoradiation for stage III 
or IV disease to allow for potential organ preservation. Total laryngectomy is still 
indicated for salvage therapy (after radiation if there is persistent disease) and in 
advanced T4 lesions, including those with significant tongue base invasion or 
destruction of cartilage.[74, 75] 
 
Concurrent chemoradiotherapy is however associated with significant acute and late 
toxicities because of its radiosensitization effects such as severe mucositis that may 
prevent oral feeding, leading to significant weight loss and often requiring a break in the 
radiation treatment.[77] In addition, radiation produces profound hypofunction of salivary 
gland tissue with consequent xerostomia, a major cause of distress. Furthermore, TL 
after failure of concurrent chemoradiation therapy is associated with high complication 
rates because of wound healing difficulties.[78] 
 
Laryngeal preservation in the form of treatment with concurrent chemoradiation is an 
attractive option for patients who prefer not to have their larynx removed. However, the 





what constitutes a preserved larynx.  From an oncological perspective, the presence of 
a larynx that is free of oncologic disease is considered a preserved larynx. It has been 
suggested that organ preservation should include more than the presence of the organ 
in situ, but also an organ with useful function. Therapeutic radiation with concurrent 
chemotherapy can have not only acute but also chronic effects on the larynx and 
pharynx including: chondronecrosis resulting in an insensate larynx that does not 
protect the airway and causes chronic pain and inflammation; dysfunctional pharyngeal 
constrictors and muscle fibrosis resulting in impaired swallowing; narrowed airway 
resulting in shortness of breath;  and chronic aspiration from post-radiation edema. 
Some considerations to assess whether a larynx is preserved and functional include 
whether the patient's voice is audible and clear, whether the patient can swallow all 
consistencies of food safely without signs of symptoms of aspiration, whether the 
patient has preserved lung function and is devoid of dyspnea at rest and on exertion, 
and whether the patient is pain free. As such, an assessment of end organ function 
once the patient is determined to be disease free would be appropriate. This can be 
achieved by using patient centered questionnaires, that address voice, swallowing, and 
quality of life. Laryngeal function has been poorly defined to date and is an active area 
of research. 
 
2.8.2 Surgery for laryngeal cancer 
Surgical approaches in treating laryngeal cancer range from microlaryngeal approaches 
to total laryngectomy. Treatment must consider the best approach for resecting the 





used to describe procedures that attempt to preserve speech and swallow through 
partial organ preservation. Patients can be considered for conservation laryngeal 
surgery if one functional cricoarytenoid joint and one laryngeal valve (epiglottic, false 
vocal cord or true vocal cord) can be reserved. Surgical approaches can further be 
divided into closed endoscopic and open procedures.  
 
2.8.2.1  Transoral laser microsurgery 
Transoral laser microsurgery (TLM) is one form of closed endoscopic surgery. This 
technique was first introduced in the 1970s and has been consistently evaluated for its 
oncologic effectiveness and functional outcomes with excellent results into the modern 
era.[79-81] This approach is often used in early-stage disease and has the benefit of 
reduced morbidity compared to open surgical management or nonsurgical 
strategies.[79] The tumor is resected using a laser (often carbon dioxide) coupled to an 
operating microscope. This is used in the treatment of T1, T2, and select T3 tumors. 
Contraindications include inadequate transoral access because of the patient’s 
anatomy, including prominent teeth, trismus, large tongue and narrow mandibular arch. 
Further, the tumor cannot involve bilateral arytenoids nor have subglottic extension 
greater than 1cm. Advantages of transoral laser microsurgery (TLM) to open 
approaches include reduced patient morbidity, faster recovery, preservation of laryngeal 
function, and the possibility of avoiding tracheostomy. The TLM technique has 
challenged the traditional principle of en bloc resection, and when applied appropriately, 
offers equivalent oncologic outcomes regardless of whether the tumor is sectioned or 





compared to radiotherapy for early laryngeal malignancy.[84] The importance of 
negative surgical margins cannot be overstated in order to achieve these outcomes. 
 
For endolaryngeal surgery, advantages include treatment in a single sitting, minimal 
absence from employment, certainty of removal of the specimen and the ability to 
assess margins surgically. Importantly, it also allows further laryngeal surgery or 
radiotherapy in case of recurrence. The disadvantage of transoral laser surgery is that it 
can affect the voice quality and access is sometimes difficult. It also requires a general 
anesthetic and may need repeated operations for which patients may not be fit.  
 
2.8.2.2 Transoral robotic surgery 
Transoral robotic surgery (TORS) for the treatment of laryngeal cancer is a developing 
field. TORS has been most frequently applied in cancers of the oropharynx but it is now 
included as a method of closed endoscopic laryngeal surgery. TORS use in laryngeal 
cancers, particularly of the supraglottis, has been explored and it has favorable 
preliminary results.[85] Advancements in robotic technology, instrumentation and 
improvement in protocol must be made before TORS is used in routine treatment of 
laryngeal cancers.[86] Currently, TLM is usually superior to TORS for glottic cancer 
because of the improved access and superior cost profile.[87] 
 
2.8.2.3 Vertical Hemilaryngectomy 
This approach is used in the treatment of select T1, T2, T3 and rarely T4 glottic 





bloc. Contraindications include fixed true cord, posterior commissures or interarytenoid 
involvement, cricoid cartilage involvement, and extralaryngeal spread. Variations on this 
approach include the frontolateral and posterolateral vertical hemilaryngectomy. 
Frontolateral vertical hemilaryngectomy can be used to treat lesions involving the 
anterior commissure and can involve up to one-third of the contralateral vocal cord. 
Posterolateral vertical hemilaryngectomy can be used for lesions that involve the 
unfixed ipsilateral arytenoid. Studies have found 83.1% for T1 and 67.2% for T2 5-year 
survival with this surgical approach.[88] 
While reported control rates after open partial laryngeal surgery for small tumors are 
probably as good as the other modalities, there is only a very limited role for open 
partial surgery for T1 and small T2 tumors. This is because the approach carries more 
morbidity with poorer outcomes than TLM or TORS. Its only role is for a patient whose 
access transorally is not possible, and who has refused radiotherapy. In addition, there 
may also be a limited role in low volume recurrences following radiotherapy.[89] 
2.8.2.4 Supraglottic laryngectomy 
Supraglottic laryngectomy can be considered in T1, T2 and T3 supraglottic tumors. This 
procedure involves removal of the structures superior to the true vocal cords. Surgical 
resection leaves a portion of the thyroid cartilage and both arytenoid cartilages. The 
patients must have bilateral vocal cord mobility, lack of cartilage involvement, limited 
base of tongue involvement, no pyriform sinus involvement, and good pulmonary 
reserve. Many patients will have some degree of aspiration immediately after the 






2.8.2.5 Supracricoid partial laryngectomy 
Select T2, T3 and T4 glottic and transglottic cancers are candidate for a supracricoid 
laryngectomy. This procedure includes the same resection of supraglottic laryngectomy 
with the addition of the true vocal cords and entire thyroid cartilage. The cricoid 
cartilage, hyoid bone and at least one arytenoid are preserved. This procedure is 
adequate in treating tumors that extend to the preepiglottic and paraglottic space. The 
remaining surgical defect is reconstructed using a cricohyoidopexy (if the epiglottis is 
removed) or cricohyoidoepiglottopexy (if the epiglottis is preserved). Again, pulmonary 
function is important as with supracricoid laryngectomy. One recent study showed a 5 
year local control rate of 94%.[90] This technique can also be used in the salvage 
setting with success in appropriately selected patients.[91] 
 
2.8.2.6 Near Total laryngectomy 
Near total laryngectomies are done in select large T3 and T4 lesions that are not 
candidates for the above-mentioned procedures. One hemilarynx and the anterior 
portion of the contralateral cord are resected. The ipsilateral cricoid and the proximal 
trachea can be removed. Unlike the previously mentioned procedures, a permanent 
tracheostomy is needed. Contraindications include tumor involvement of the 
interarytenoid and postcricoid and inability to preserved two-thirds of the contralateral 
vocal cord. Studies have found that disease control rates were comparable in near total 
laryngectomy compared to total laryngectomy/laryngopharyngectomy.[92] This 






2.8.2.7 Total laryngectomy 
Total laryngectomy involves complete removal of the larynx. It was first successfully 
performed by Theodor Billroth in 1873.[93] The procedure removes the larynx, hyoid 
bone, thyroid cartilage, cricoid cartilage and proximal traches. A portion of the pharynx 
and base of tongue may also be resected. There is mobilization of the trachea and once 
the trachea is entered it is sutured to the skin, completely separating the trachea from 
the pharynx. The pharyngeal mucosa is closed using a running suture. Primary total 
laryngectomy is indicated in advanced disease that is not amenable to partial 
laryngectomy, concurrent chemoradiation or radiotherapy alone. Specifically, tumors 
that have penetrated through cartilage, invasion into the extralaryngeal soft tissue of the 
neck and extensive involvement of the base of tongue are suitable indications for this 
procedure. Also, pulmonary status and medical comorbidities and cognitive function 
may define the treatment options for a given patient. Total laryngectomy is an effective 
treatment for advanced cancers but has an overall recurrence rate of 37% in stage II 
and IV glottis tumors.[94] Swallowing, with appropriate reconstruction is usually 
excellent and a primary or secondary tracheoesophageal puncture for voice 
rehabilitation should be considered in patients undergoing total laryngectomy.  
 
 
Salvage total laryngectomy (TL) is indicated for chemoradiation, radiation, or partial 
laryngeal surgical failures. Salvage TL can be technically more difficult and caries a 







2.8.3 Treatment outcomes 
There is debate whether laryngeal cancer is best treated with radiation, chemoradiation 
or primary surgery. Options for treatment are largely determined by the stage of the 
disease, but many times there are multiple acceptable standard-of-care treatments for 
the same cancer. Single modality treatment with surgery or radiation is considered 
acceptable primary treatment for early glottic or supraglottic cancers. The modality of 
therapy selected is largely determined by the surgical and radiation experience of the 
treating physicians and considering the functional impact of the treatment. The goal is 
always to minimize morbidity of treatment and the number of treatment modalities used) 
and maximize therapeutic outcomes. When surgery is thought to leave good voice and 
swallowing function, such as in selected glottis and supraglottic tumors, surgery is 
limited and the likelihood of adjuvant chemoradiotherapy is low (triple modality therapy). 
Surgery has the benefit of pathologically staging the neck, assessing the primary tumor 
and neck for negative features (perineural invasion, lymphovascular invasion and 
extracapsular extension) and potentially being a shorter and more cost-effective 
treatment option.[95, 96] However, when the likelihood of triple modality therapy or loss 
of function are high, nonsurgical modalities are preferred when oncologic outcomes are 
not compromised.  
 





The primary objectives of laryngeal cancer treatment are cure, long-term survival and 
the preservation of a functional larynx. This has led to a variety of definitions of 
laryngeal cancer outcomes.   
 
 2.9.1 Overall Survival for Laryngeal Cancer  
Overall survival is defined as the rate at which patients with laryngeal cancer 
survive from all causes. Mortality events are due to deaths from cancer and other 
causes.  
 
2.9.2 Disease-specific survival of laryngeal cancer 
Disease-specific survival of laryngeal cancer is defined as the rate of survival 
from laryngeal cancer. Deaths are from laryngeal cancer treatment related 
complications, primary cancer progression or cancer recurrence. Other deaths 
are commonly treated as a censored event.  
 
2.9.3 Laryngectomy-free survival of laryngeal cancer 
Laryngectomy-free survival is defined as the number of patients with laryngeal 
cancer who survive with an intact larynx. This can be defined as the number of 
surviving patients who have not undergone a laryngectomy.  
 
2.9.4 Laryngo-esophageal dysfunction-free Survival 
Complications following laryngeal preservation protocols can include aspiration, 





functional and some patients require a tracheostomy for pulmonary toilet 
(suctioning of secretions from the lungs) and airway protection. Laryngectomy for 
an incompetent larynx is required in some situations even in the absence of 
cancer. Furthermore, complications from a pharyngeal and esophageal 
perspective can result in failure to achieve esophageal speech or speech with 
tracheoesophageal prosthesis. Esophageal stenosis resulting in gastrostomy 
(feeding) tube dependence can also occur. Although laryngeal preservation is an 
important component of quality of life, even though the larynx may be present it is 
not necessarily functional following radiotherapy +/- chemotherapy. This has led 
experts in the area to propose the outcomes of laryngo-esophageal dysfunction-
free survival. Events for this outcome would include death, local relapse, totally 
laryngectomy, tracheostomy at >= 2 years or feeding tube at >= 2 years.[97] 
 
2.10 Surveillance for Recurrence of Laryngeal Cancer 
Close follow-up is needed for patients with laryngeal cancer. Traditional tenets of 
surveillance of laryngeal cancer center on clinical symptoms, office-based or operative 
laryngoscopy and biopsy and imaging studies such as CT or MRI. Although the timing 
of surveillance is not standardized across centers, clinic visit intervals are often every 2-
3 months during the first 2 years and 6-8 months during years 3-5. Current National 
Comprehensive Cancer Network Guidelines recommend baseline posttreatment 
imaging of the primary within 6 months followed by further reimaging as indicated based 





Patients without evidence of disease 5 years after treatment can be examined annually 







CHAPTER THREE: LITERATURE REVIEW OF SUBGLOTTIC CANCER 
3. 1 Introduction to Subglottic cancer 
Subglottic carcinoma is a rare variant of laryngeal cancer. It is traditionally thought that 
subglottic carcinoma has a worse prognosis than tumors arising in other subsites of the 
larynx (supraglottis and glottis), owing to its tendency to present in advanced stages, 
with a high incidence of cartilage invasion and extralaryngeal spread. The incidence of 
subglottic carcinoma varies among series, mainly because there is no uniform definition 
of the upper boundary of the subglottis. The extent of the tumor may be difficult to 
define because subglottic carcinoma may spread through the submucosa without visible 
mucosal changes. There is also a rich lymphatic network in the subglottis draining to the 
prelaryngeal and paratracheal lymph nodes, which are usually not involved by cancers 
arising in other laryngeal subsites. Current literature indicates that early stage subglottic 
carcinoma can be treated using radiotherapy or chemoradiotherapy with high 
locoregional control and survival rates. In advanced stage subglottic carcinoma, a 
combination of surgery followed by radiotherapy or chemoradiotherapy likely results in 
comparable outcomes as in advanced carcinoma from the rest of the larynx. We 
performed a scoping literature review to determine the following: 
 a) Anatomic boundaries and definition of the subglottic larynx 
 b) Incidence and epidemiology of subglottic carcinoma 
 c) Stage presentation of subglottic carcinoma 
 d) Treatment regimens for subglottic carcinoma 
  e) Survival outcomes including locoregional control, disease specific survival, 





 f) Propensity for stomal recurrence 
 g) Quality of life outcomes 
 
3.2 Literature Search Strategy 
We performed a literature search to retrieve all articles on subglottic cancer. We 
included all single arm and comparative studies which reported on the incidence and 
outcomes of patients with subglottic cancer. The literature search performed on 
September 1, 2020 and retrieved 1244 citations. Randomized controlled trials, 
observational studies, case series and case reports (more than 3 patients) were 
included. The study population was limited to patients diagnosed with squamous cell 
carcinoma of the subglottis, excluding other histologies. We excluded non-English 
articles. We excluded patients with primary glottic cancer with subglottic extension. All 
treatment interventions were included. We reported on the incidence of subglottic 
carcinoma, the treatment modalities used and survival outcomes including: overall 
survival; disease-specific survival; locoregional control; and larynx preservation.  
 
The search strategy is outlined in Appendix A. From the MEDLINE search we retrieved 
940 titles, from EMBASE 618 titles and from CINAHL 319 titles. The reference lists of all 
included articles were also reviewed. Once we removed duplicates the number of titles 
were 1432 titles. The full papers of 59 studies were reviewed. The PRISMA flow 








Figure 1 Prisma Flow Diagram 




























 Additional records identified 
through other sources 
(n =  54 ) 
Records after duplicates removed 





Full-text articles assessed 
for eligibility 
(n =  59 ) 
Full-text articles excluded, with 
reasons 
(n = 34) 
Case Report n=11 
Review article n=11 
Glottic cancer n=4 
Outcomes not reported n=3 
Subglottic outcomes not 
reported separately n=4 
Article not available n=1 
Studies included in 
qualitative synthesis 
(n = 25 ) 
Studies included in 
quantitative synthesis 
(meta-analysis) 







Excluded articles and reasons for exclusion are listed in table 4. Included articles are 
listed in table 5.  
Table 4 Excluded articles and reasons for exclusion 
Author  (year) Title Reason for Exclusion 
Berger G (1985)[99] Primary subglottic carcinoma masquerading 


















Prognosis of subglottic carcinoma: Is it really worse? Review article 
De Souza RP 
(2007)[103] 
Value of computed tomography for evaluating the 
subglottis in laryngeal and hypopharyngeal 
squamous cell carcinoma 
Outcomes not reported 
Delaere P 
(2007)[104] 
Organ preservation surgery for advanced unilateral 
glottis and subglottic cancer 
Glottic cancer and non-
epidermoid histology 
Dogan E (2014)[105] Elective superior mediastinal dissection for laryngeal 









The pathology and management of subglottic cancer Review article 
Flynn JM 
(1964)[107] 
Subglottic carcinoma of the larynx Case Report 
Gorphe P 
(2016)[108] 
Laryngo-esophageal Dysfunction-free Survival in a 












Subglottic cancer. Case Report 
Harris HH 
(1968)[111] 
Surgical limits in cancer of the subglottic larynx Review article 
Harrison DF 
(1971)[7] 
The pathology and management of subglottic cancer Review article 
Harrison DF 
(1975)[112] 
Laryngectomy for Subglottic Lesions Outcomes not reported 
Huang YC 
(1993)[113] 
The management of advanced subglottic carcinoma 




An iridium-192 applicator for the treatment of 





Endoscope-assisted conservative resection and 




Subglottic and tracheal malignancies Review article 
Lassaletta L 
(1998)[117] 
Synchronous glottis glandular cell tumor and 
subglottic spindle cell carcinoma 
Case report 
Liang J (2020)[118] Which risk factors are associated with stomal 
recurrence after total laryngectomy for laryngeal 







Management of paratracheal lymph nodes in 






Classification of subglottic tumors and discussion of 




Subglottic carcinoma treated with surgery and 




Submucosal squamous cell carcinoma of the 
subglottis 
Case report 
Saleh EM (1992)[23] Computed tomography of primary subglottic cancer: 
clinical importance of typical spread 
Outcomes not reported 
Sessions DG 
(1975)[123] 
Laryngeal carcinoma involving anterior commissure 
and subglottis. 
Review article 
Stell (1975) [124] The behaviour of cancer affecting the subglottic 
space 
Article not available 
Succo G (2017) Supratracheal partial laryngectomy: indications, 






Role of radiotherapy in Cancer of the larynx as 




A case of subglottic carcinoma effectively treated 





Influence of risk factors on stomal recurrence after 





Use of a videolaryngoscope with a tube guide for 








Table 5 Articles included in literature review and patient characteristics 
Included 
Study 
Type of Study Subglottis 
Definition 
(upper border) 




































6 2 1981-1190 1 7 7/8 
cases 
SCC 

















































NR 2 9 1995-2019 9 2 All SCC 69 11/0 5 
Lee KC 
(2020)[133] 
SEER database NR 0 37 2005-2015 37 0 All SCC 67 NR 5 
Marchiano E 
(2016)[18]d 






5 mm below 
cords 



















































































21 0 2005-2010 12 9 20/21 63 19/2 5 
Zhu F (2019)b NCDB NR 249 2004-2014 249 0 NR 69 NR 3.1 
NR Not Reported 
NCDB National Cancer Database 
SCC Squamous Cell Carcinoma 
a Treatment was defined as primary treatment. Numbers do not add up to total number of patients in 
each study as some patients declined treatment.  
b Abstract only 
c 1patient no treatment (denied by patient) 
d Stage unknown in 30 patients. Staging was only available from 2004 and onward.  
e2 patients did not receive treatment 
 
We assessed the methodologic quality using the New-Castle Ottawa scale (Appendix B) 
for cohort studies, where a higher score reflects better methodology.  The study quality 
of most studies was poor (Table 6), with only 9 studies with a score of 6 or more. A 
large number of studies lost points for the category "comparability" as they did not 
account for confounding factors that impacted survival such as stage, age and patient 
comorbidity.  
Table 6 Assessment of methodologic quality of included articles using the Newcastle-
Ottawa Scale 






3 0 1 3 
Dahm JD 
(1998)[129] 
3 1 3 6 
Gairola A 
(1992)[130] 
1 0 1 2 
Garas J 
(2006)[131] 
3 0 2 4 
Guedea F 
(1991)[20] 
3 0 3 5 
Hata M (2013)[71] 2 0 2 5 
Haylock BJ 
(1993)[15] 
2 0 2 4 
Hill-Madsen 
(2019) 
3 2 3 8 
Jumaily M 
(2020)[11] 
3 2 3 8 
Komatsubara Y 
(2020)[132] 
2 0 1 3 
Lee KC (2020) 4 2 3 9 
Marchiano E 
(2016) 
4 2 3 9 
Nahavandipour A 
(2019)[134] 
4 1 3 8 
Paisley S 
(2001)[12] 
3 0 3 6 
Santoro R 
(2000)[135] 
4 2 2 8 
Sessions DG 
(1975)[1] 
3 1 1 5 
Shaha AR 
(1982)[2] 
4 0 3 7 






4 0 2 6 
Su WF (2003)[136] 4 0 2 6 
Vlckova K 
(2019)[137] 
1 1 2 4 
Warde P 
(1987)[138] 
3 0 3 5 
Weiss B (2018)[3] 1 0 3 3 
Yu H (2019) 2 1 3 6 
Zhu F (2019)[139] 4 2 3 9 
 
3.3 Anatomic boundaries and definition of the subglottic larynx 
The subglottic larynx is located between the vocal folds and the trachea. Despite this 
simple definition, the anatomic boundaries of the subglottis are controversial. The 
laryngeal ventricle clearly separates the supraglottic and glottis regions, whereas the 
glottis and subglottic regions are fused with no visible boundary, because they have a 
common embryological origin. There is general agreement that the inferior border of the 
subglottis is the inferior border of cricoid cartilage but there is no agreement about the 
superior border, which is considered to be an imaginary line passing 5mm below the 
free margins of the vocal folds by some authors[16] and from 0 to 1 cm below the vocal 
folds by others.[24] It may also be defined as 1 cm below the apex of the laryngeal 
ventricle.  
 
Ferlito and Rinaldo (2000) published a review of subglottic carcinoma in 2000 and they 
reported the many different definitions of the upper border of the subglottis according to 




makes our understanding of the nature of subglottic carcinoma difficult and reporting 
data regarding subglottic carcinoma inconsistent.  
 
As demonstrated in our review (Table 5), 13 studies did not specify the boundaries of 
the subglottis, with some authors either not reporting a definition or simply stating that 
the tumor was "primarily in the subglottis". The majority of the papers reported the 
superior border of the subglottis as starting 5mm below the level of the cords while 2 
papers reported the superior border as 1 cm below the level of the ventricle.  
 
This variable definition in the superior border of the subglottis may result in some 
cancers that are in fact glottic cancers being misclassified as subglottic cancers 
(misclassification bias). As described below, glottic cancer may have improved survival 
compared to subglottic carcinoma therefore, this misclassification of subglottic tumors 
may impact the survival outcomes reported in our review.  In the future, explicitly 
defining the boundaries of the subglottis and excluding those glottic cancers that exhibit 
subglottic extension will allow for a more accurate estimate of survival outcomes. 
 
3.4 Epidemiology of Subglottic Carcinoma 
Cancer arising from the subglottic larynx is rare, ranging from 0-8.7% of all laryngeal 
cancers (Table 7). We performed a pooled analysis of the proportion of subglottic 
carcinoma amongst all laryngeal cancers and found the proportion of subglottic 
carcinoma to be 2.1% (95% CI 1.4-3.0%) (Figure 2). As described above the difference 




subglottic cancer (Table 5). The rarity of primary subglottic cancer has been attributed 
to decreased mucosal trapping in the upper airway and a consequent minimal contact 
with potential carcinogens.[24] Whereas, the glottis and supraglottis have direct contact 
with potential inhaled carcinogens, the subglottic mucosal is partially protected from 
exposure by the vocal cords which overhang the subglottic mucosa. This theory, 
however, has not been demonstrated in animal or human studies. 
 
Table 7 Published studies reporting the proportion of those with laryngeal cancer where 
the primary location was subglottic  











650 2 0.3 These tumors included 
adenoid cystic carcinomas 
Dahm 
(1998)[13] 
2201 39 1.8 In this series 28 tumors 
(71.8%) were squamous cell 
carcinomas and 4 (10.3%) were 
chondrosarcomas. The other 
tumors included sarcoma 
(n=2), small cell carcinoma 
(n=2), adenoid cystic 
carcinoma, lymphoma and 
undifferentiated carcinoma 
Garas (2006) 1098 15 1.37 All squamous cell carcinoma, 
tumors originating in the 




319 19 6.0 All squamous cell carcinoma 
Haylock (1993) 263 23 8.7 Some patients may have had 
glottic cancer with subglottic 
extension given high incidence 






280 11 3.9 All squamous cell carcinoma 
Kleinsasser 
(1991)[141] 




2035 140 6.9 Tumors were included that 
originated from the 
undersurface of the vocal cord 
which would now be classified 
as glottic cancers using TNM 
staging  
Lee KC (2020) 3221 37 1.15 Only early stage T1/T2N0 
laryngeal cancer treated with 
radiation were included 
MacNeil 
(2015)[36] 
4927 89 1.81 Administrative data so coding 
errors may have been present. 
Nahavandipour 
(2019) 
8748 142 1.62 Administrative data so coding 
errors may have been present. 
Tumors in addition to 




2908 55 1.9 All tumors were squamous cell 
carcinomas 












1011 42 4.1 Tumors also originated from 
the undersurface of the vocal 
cords and would now be 
classified as glottic cancers 
using TNM staging 




Yu (2019)[17] 1815 23 1.3 Tumors in addition to 




Figure 2. Forest Plot of the proportion of those with laryngeal cancer where the primary 
location was subglottic  
 
For several reasons, it is difficult to establish the true proportion of subglottic carcinoma. 
First, as previously mentioned, there is no uniform definition of the upper border of the 
subglottic region. Second, in some reports, subglottic carcinoma and glottic carcinomas 
with subglottic extension were grouped together. Third, it is not always possible to 
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper 
rate limit limit Z-Value
Bittesini 1991 0.003 0.001 0.012 -8.163
Dahm 1998 0.018 0.013 0.024 -24.852
Garas 2006 0.014 0.008 0.023 -16.461
Hata 2013 0.060 0.038 0.091 -11.664
Haylock 1993 0.087 0.059 0.128 -10.744
Komatsubara 2020 0.039 0.022 0.070 -10.392
Kleinsasser 1991 0.000 0.000 0.004 -5.864
Lederman 1970 0.069 0.059 0.081 -29.747
Lee 2020 0.011 0.008 0.016 -26.942
MacNeil 2015 0.018 0.015 0.022 -37.353
Nahavandipour 2019 0.016 0.014 0.019 -48.511
Paisley 2002 0.019 0.015 0.025 -29.007
Santoro 2000 0.016 0.012 0.022 -28.451
Shaha 1982 0.010 0.007 0.015 -21.401
Silvestri 1992 0.002 0.000 0.015 -6.111
Stell 1975 0.042 0.031 0.056 -19.913
Su 2003 0.052 0.022 0.119 -6.317
Yu 2019 0.013 0.008 0.019 -20.756
0.021 0.014 0.030 -20.212




distinguish between primary glottis and primary subglottic cancers with extension into 
neighboring region(s) and consequently, to determine the true origin of the tumor inside 
the larynx. Fourth, cancers other than squamous cell carcinoma, such as adenoid cystic 
carcinoma or chondrosarcoma, are reported together in some series. Tumors with 
different histologies have completely different clinical behaviors and should be reported 
separately.  
 Nahavandipour A et al (2019) used the Danish Cancer Registry to determine the 
trends in incidence of laryngeal cancer in the Danish population from 1980 to 2014. 
They found decreasing incidence in for the groups supraglottic cancer with an average 
annual percent change (AAPC) of -2.4 % (95% CI -3.5; -1.2%) and glottic cancer with 
an AAPC of -4.8% (95% CI -6.6%; -2.9%) but no change in incidence for subglottic 
cancer with an AAPC pf -1.1% (95% CI -2.8; 0.7).[134] No other studies have examined 
the trends in incidence of subglottic cancer over time. Some authors have suggested 
that the subglottic larynx is protected from the common carcinogens that cause glottic 
and supraglottic cancer. With the decreasing incidence of smoking and other inhaled 
carcinogens, many studies have shown that laryngeal cancer overall is decreasing in 
incidence. The stable incidence in subglottic cancer over time may indicate that this 
region of the glottis is not as susceptible to inhaled carcinogens however further studies 
with large numbers of patients are needed to demonstrate causation.   
 
3.5 Stage Presentation of Subglottic Carcinoma 
As described in the staging of laryngeal cancer in the sections above, the stage of 




disease as well as the presence of distant metastasis. Subglottic tumors can spread 
locally invading into the surrounding structures of the larynx or regionally through the 
lymphatics into the cervical lymph nodes. Strome (1999) examined the invasion patterns 
of 10 patients with subglottic carcinoma.[19] In this study, cartilage invasion was rare. 
Cancer spread was usually submucosal with paraglottic invasion, which occurred in the 
early stages of the disease and extralaryngeal extension, which occurred easily through 
potential spaces.[19] Similarly, Olofsson (1995) found that extralaryngeal spread 
through the cricothyroid membrane was common in subglottic tumors and glottic tumors 
with subglottic extension.[144] In the study by Olofsson (1995), other features of 
subglottic tumors were extensive circumferential growth and cartilage invasion.[144] A 
high rate of cartilage invasion was also demonstrated by Kurita et al (1985)  who 
conducted a histopathological study of 51 serially sectioned laryngectomy 
specimens.[145] The incidence of cartilage invasion was highest in subglottic 
carcinomas; thyroid cartilage invasion was present in 67% and cricoid cartilage invasion 
was present in 33%.[145]   
 With respect to nodal spread of disease Liu et al (2006) examined 18 fresh 
cadavers and found that the inferior surface of the vocal folds have a large number of 
lymphatic vessels and collecting chambers.[146] These lymphatic vessels anastomosed 
with each other to form a dense network, which connects with the subglottic lymphatic 
system. Lymphatic drainage of the subglottic region proceeds though the prelaryngeal 
(Delphian), pretracheal and paratracheal nodes and drainage patterns are to bilateral 




 Some have suggested that subglottic carcinoma is more likely to present with 
advanced stage disease compared to the other subsites of laryngeal cancer. We found 
no large studies that examined the stage of presentation for all subsites of laryngeal 
cancer. In those studies that reported on early and advanced stage subglottic cancer, 
summarizing the findings we found 562 patients presented with early stage disease 
while 798 presented with advanced stage disease (ratio early/advanced 0.70). Previous 
population based work by our group has demonstrated that glottic cancer presents with 
a ratio of 3.11 early stage to advanced stage (544 patients early stage/175 patients with 
advanced stage) and supraglottic cancer at a ratio of 0.34 early stage to advanced 
stage (71 patients early stage/ 208 patients advanced stage).[36] Therefore, subglottic 
cancer based on our pooled analysis appears to present at more advanced stage than 
glottic cancer but less advanced than supraglottic cancer. As described in the laryngeal 
section above, similarities between the supraglottis and the subglottis include rich 
lymphatics, bilateral lymph node drainage basins and lack of anatomic barriers to local 
spread. Given the possible misclassification of some glottic cancers as subglottic 
cancers, this may account for the higher ratio of early stage to advanced stage in 
subglottic compared to supraglottic cancers.  
 
3.6 Treatment of Subglottic Cancer 
Treatment of subglottic carcinoma varies according to the stage of the disease. Several 
studies have demonstrates that early-stage subglottic carcinoma can be managed with 
a single modality treatment, whereas advanced-stage disease requires combined 




the treatments used and reporting of outcomes varied greatly amongst the studies 
(Table 8). There were very few head to head comparisons of primary surgery versus 
radiation. In addition, the treatment regimens for laryngeal cancer have changed over 
the years. For example, studies included patients treated with antiquated radiation 
techniques, and patients treated with neoadjuvant radiation before surgery (no longer 
used at most centres). Further, transoral surgery techniques for excision of small 
laryngeal cancers have improved, partial laryngectomy techniques described above 
have largely fallen out of favour. Several studies reported outcomes for patients treated 
with partial laryngectomy techniques.  Chemotherapy was not considered standard of 
care for advanced laryngeal cancer until the publication of the RTOG 91-11 study in 
2003 which demonstrated acceptable survival outcomes and laryngeal preservation for 
patients with advanced laryngeal cancer. [74] The description of treatment outcomes 
below is limited to more recent studies using contemporary treatment practices. 
  
3.6.1 Surgical Treatment 
As summarized in table 5, surgery was used as primary treatment for subglottic cancer 
in 798 patients. Surgery can be used as a single modality treatment in early stages. 
Depending on the location of the primary tumor, a total laryngectomy is frequently 
required. However, in selected cases, extended partial laryngectomies can provide 
similar oncologic results while preserving laryngeal functions. In the case of advanced-
stage subglottic carcinoma a wide-field total laryngectomy is required, owing to the high 
incidence of extralaryngeal spread. Jumaily studied the NCDB and assess 205 patients 




treatment with surgery alone, 77 patients with surgery followed by postoperative 
radiation and 52 patients by surgery followed by postoperative chemoradiation. Total 
laryngectomy accounted for 80.5% of the cases, partial laryngectomy 8.3% and 
transoral laser surgery for 11.2% of cases. Marchiano examined the SEER database 
and found that the majority of patients with subglottic cancer were treated with surgery 
followed by radiation (317 (38.8%)), while 139 patients (17.0%) were treated with 
surgery alone.[31] They found that surgery alone was used for 9 patients with early 
stage disease and 23 patients with advanced stage disease. Surgery and radiotherapy 
was used for 18 patients with early stage disease and 66 patients with advanced stage 
disease. However, the SEER database does not report of the extent of surgery.  
 
There were two studies that reported on patients with subglottic cancer only treated with 
surgery.[3, 17] Yu examined 21 patients, of which 12 had early stage disease and were 
treated with a mix of vertical hemilaryngectomy, transoral laser microsurgery and 
supracricoid laryngectomy, the other 7 patients underwent total laryngectomy.[17] All 
patients with advanced stage laryngeal cancer in this study were treatment with total 
laryngectomy.[17] Weiss reported on 17 patients with subglottic cancer, of which 13 
patients treated with transoral laser microsurgery, and 3 were treated with 
laryngectomy.[3]  
 
From our review of the literature, options for surgical treatment of subglottic cancer 
which yield acceptable survival outcomes include transoral laser microsurgery, vertical 




subglottic cancers are amenable to microsurgery, vertical partial laryngectomy and 
supracricoid laryngectomy, whereas advanced stage subglottic cancer requires total 
laryngectomy. The data reported in the literature to date on the surgical outcomes for 
patients with subglottic cancer are limited by lack of surgical detail for population based 
studies, low numbers of patients in single centre studies, and inconsistent use of 
adjuvant treatment following surgery. A comparison of the survival outcomes for 
patients treated with surgery versus radiation is listed in table 8 however caution should 
be used in comparing the results given the representativeness and selection of both 
cohorts. Due to the heterogeneity of the data meta-analysis could not be performed for 
survival comparing different treatment regimens. Accepting the limitations of the 
included studies the 5 year overall survival for patients treated with surgery range was 
46.4-73.9%. One study reported 5 year overall survival separately for early stage and 
advanced stage subglottic cancer which found 63% for early stage and 57% for 
advanced stage.  
 
3.6.2 Chemoradiation Treatment 
Early-stage cases can be treated with radiation fields directed at the larynx with a 1- to 
2-cm margin.[128] Radiation fields for advanced-stage cases usually include the larynx, 
bilateral cervical, supraclavicular, and upper mediastinal lymph nodes and total dose 
usually ranges between 50 and 75 Gy.[12, 71, 128]  
  
Nine studies reported on the survival outcomes of patients with subglottic cancer treated 




retrospective reviews. Hill-Marsden reported on 146 patients from the Danish Cancer 
Registry, 134 (92%) patients were treated with primary RT and 10 (7%) with RT and 
surgery in combination.[10] Over the study period the provided RT dose increased due 
to changing practices over time. Patients were treated with different radiotherapy 
regimens including standard RT regimens, accelerated RT and accelerated 
hyperfractionated RT. In a study by Marchiano et al using the SEER database, primary 
radiotherapy was used in 277 patients.[18]  The SEER database is limited by lack of 
information on chemotherapy administered or radiotherapy regimens and whether they 
changed over time. Jumaily et al used the NCDB database to study 549 patients treated 
for sublgottic cancer, 344 of which were treated with primary radiation.[11] The 
remainder of the studies reporting survival by treatment type were single centre case 
series.  
 
Unfortunately, due to the heterogeneity of the data we were not able to perform meta-
analysis for any of the survival outcomes by treatment. The survival results by treatment 
are summarized in table 8.  Based on the studies presented in Table 8, the 5 year 
overall survival for patients treated with primary radiation ranged from 26-57.5%. For 
patients with stage I/II disease 5 year overall survival range was 57-63%. For advanced 
stage disease 5 year overall survival was 38% as reported in Jumaily et al.[11]  
 
Visual inspection of the data in Table 8 demonstrates that 5 year overall survival 
appears to be lower for patients treated with primary radiation versus primary surgery. 




 1) The definition of subglottic cancer differs amongst the studies which may 
impact the survival if some of the tumors are misclassified as primary glottic cancers 
with subglottic extension; 
 2) There is selection bias in the patients treated with surgery and radiation, as 
the data reported are limited to population-based and single centre studies. There are 
no randomized trials comparing surgery and radiation for subglottic cancer and the 
studies that report head to head comparisons do not specify the selection criteria for 
each treatment.  
 3) The treatment practices for radiation and surgery have evolved over time 
which makes comparison of survival outcomes between studies challenging.  
 4) Details of the extent of surgery is lacking in some studies as well as the 
indications and extent of adjuvant treatment. These factors may impact long-term 
survival.  
 
Table 8 Survival Outcomes of Subglottic Carcinoma by Treatment  
Study Treatment LRC DSS OS 5 year 
Haylock 
(1993)[15] 
RT  78.3% 57.5% 
Hill-Madsen 
(2019)[10] 
RT (1% patients 
treated with Sx 












 RT or CRT    
 I/II 
III/IV 
  57 
38 
Lee (2020)[133] RT 
I/II 












Paisley (2002)[12] RT 56 66.9 50.3 
Warde 
(1987)[138] 
RT  61 26 
Yu (2019)[17] Surgery  73.9 73.9 
Zhu (2020)[139]  Surgery 
RT 




LRC: Locoregional Control 
OS: Overall Survival 
DSS: Disease Specific Survival 
 
3.7 Survival Outcomes of Subglottic Carcinoma 
Traditionally, subglottic carcinoma is regarded as an aggressive tumor with a worse 
prognosis compared with other laryngeal subsites. Possible explanations for the 




extralaryngeal spread, a high incidence of paratracheal and mediastinal lymph node 
metastases (which may be left untreated during surgical or radiotherapeutic treatment), 
thyroid gland involvement, and stomal recurrence. In addition, these tumors usually 
remain asymptomatic until advanced stages, because submucosal spread through 
potential spaces (ie paraglottic space) is common and may cause a delay in diagnosis.  
 
There is controversy in the literature about the prognosis and treatment results of 
subglottic carcinoma. Some reports indicate very low survival and locoregional control 
rates when compared with other laryngeal subsites, whereas others observed 
comparable outcomes, despite unfavorable features listed above. As described in Table 
9, the 5 year overall survival range was 26-80%. When only population-based studies 
were included the 5 year overall survival range was 41.5-48.7%. 5 year disease free 
survival range was 25-90% when all studies were included and 53.7-57% when only 
population-based studies were included. Finally, local regional control ranges from 53.7-
57% in the two studies that reported it. Hill-Madsen et al. were the only authors to report 
laryngectomy free survival in their population based study in Denmark. They reported 5 
year LFS of 37% (95% CI 29-45).[10] Previous population-based research by our group 
using Ontario administrative data found a 5 year overall survival for patients with glottic 
and subglottic cancer was 67.1% and 39.5%, respectively.[36] Five-year laryngectomy 
free survival was 55.5% for glottic cancer patients and 28.0% for supraglottic cancer 
patients.[36] This suggests that the survival of patients with subglottic cancer may not 
be worse than the other laryngeal sites, and the survival outcomes lie somewhere 




studies is heterogenous and confounding factors that are known to impact survival of 
patients with laryngeal cancer such as age, stage, comorbidity, and treatment 
completion are not adjusted for.  
 
Table 9. Literature review of subglottic carcinoma treatment and survival outcomes 












  I/II III/IV RT Surgery     
Cassidy (2012) [128] 18 7 12 14 5 83 66 44 NR 
Dahm (1998)a [13] 28 19 9 10 17 61.5 46.2 58 NR 
Gairola (1992)b 
[130] 
8 1 7 5 3 NR NR 37.5 12.5 
Garas(2006)c [131] 15 3 12 6 9 NR 25 NR NR 
Guedead (1991)[20] 6 3 3 6 0 NR NR 33 16.7 




74 63 80 NR 
Haylock(1993)[15] 23 13  10 23 0 NR 78.3 57.5 NR 
Hill-Madsen 
(2019)f[10]  













330 344 205 NR NR 48.2 NR 
Komatsubara(2020)
[132] 
11 9 2 9 2 NR 61.4 NR 9.1 







456 NR  53.7 41.5 NR 
Nahavandipouri 
(2019)[134] 
142 NR NR NR NR NR NR 45 NR 




43 0 56 66.9 50.3 NR 
Santoro(2000)[135] 49 17  32 
 
6  25 NR NR 56 43.9 
Sessions(1975)[1] 5 1 2 0 3 NR NR 66.7 NR 
Shaha(1982)[2] 16 3 13 16 
 
0 NR NR 77 NR 
Smee (2008)[6] 10 6  4 4 6 90 NR NR NR 




NR NR 50 NR 




Warde (1987)[138] 23 9 14 22 0 74 61 26 NR 
Weiss(2018)[3] 13 4 9 0 13 46 90 79 NR 







Zhu (2010)[139] 249 24
9 
0 NR NR NR NR 31 (10yr) NR 
Pooled results 2335 56
2l 
798 968 799     
 
 
Abbreviations: TL-Total laryngectomy; PL-partial laryngectomy; RT-radiation; CRT-
chemoradiation; Sx- Surgery undefined; NR-not reported; LRC-Locoregoinal Control; 
DSS-Disease Specific Survival; OS-Overall Survival. 
Shaded studies represent crude survival rates not proportionate survival. 
a No difference in survival amongst treatment groups. 5-year overall survival 44% RT 
alone, 50% Surgery alone, 100% combined therapy. 1 patient opted for palliative care. 
Crude survival rates reported.  
b RT used as neoadjuvant treatment in 4 patients with planned laryngectomy after. 
Reported as crude survival rate at 3 years.  
c 3-year crude survival reported for patients treated with TL 0%, TL + adjuvant RT 40%, 
RT 33.3%, and RT + salvage TL 0%.  
d 4-year crude overall survival reported. One patient had carcinoma in situ 
e 5-year crude survival for patients treated with CRT 100% and RT 92%. 4 surgical 




f 10 patients in surgery group treated with neoadjuvant RT and planned surgery 
g All patients had Stage I/II subglottic cancer 
h Population-based SEER study in which no further detail on extent of surgery. Some 
Surgery patients treated with adjuvant radiation. 
i OS estimation from KM curve at 5 years 
J 2.5 year crude survival rate 
k 10 yr OS reported 
l Studies that only included early stage cancers were excluded from pooled result 
 
3.8 Stomal Recurrence 
Stomal recurrence is one of the most feared types of recurrence during patients with 
laryngeal carcinoma. The reported incidence of stomal recurrence ranges from 4.8-
43.9%.[17, 20, 130, 132, 149] The pathogenesis of stomal recurrence is still unknown 
but various factors, such as tumor site and stage, positive tracheal margins, thyroid 
gland invasion, tumoral implants, prior tracheostomy, and paratracheal lymph node 
metastases are considered possible causes.[150] As indicated in Table 9, the majority 
of the studies did not report stomal recurrence, and the studies that did report on stomal 
recurrence have a small sample size. Therefore, given the limitation of reporting in 
stomal recurrence no conclusions can be made regarding the incidence relative to other 
laryngeal cancer sites, or the risk factors for stomal recurrence.   
 
3.9 Quality of Life Outcomes 
Only one study reported on voice and swallowing outcomes in patients treated for 




treated for all three subsites of laryngeal cancer, glottic, supraglottic and subglottic. 
They found that the voice outcomes were worst in the glottic cancer group. In the 
subglottic group, the number of patients with "bad voice" did not change pre-and post-
treatment.[137] Among the patients with subglottic cancer, the number of patients with 
"no swallowing dysfunction" increased after treatment.[137] This study is limited by 
reporting of a non-validated instrument for measurement of voice and swallowing 
outcomes, small numbers of patients with subglottic cancer (n=4) and incomplete follow-
up data.  
 
CHAPTER FOUR: RATIONALE FOR RESEARCH APPROACH 
4.1 Limitations of existing studies 
There are several methodological limitations of the existing studies on survival 
outcomes of patients with subglottic carcinoma. Furthermore, there is only one 
population-based study that reports on laryngectomy-free survival.[10] These limitations 
are summarized here: 
I. Study centers: most prior studies were institutional case series limited to a single 
center which limits study generalizability.  
II. Sample size: most prior studies were limited by small sample size (less than 50 
people). Small sample size can limit adjustment for important confounding factors 
because of concerns about over-fitting in statistical models. Over-fitting in a 
statistical model occurs when it has more variables than the amount of available 




III. Type of treatment: the types of treatments administered in previous studies 
varied from study to study. In some of the previous studies there was no data on 
chemotherapy. Furthermore, the methods of radiotherapy have changed in 
recent years. Only one study examined the trends in survival over time.[134]  
IV. Study design: All the existing studies are observational in nature. Most are 
institutional reviews which are limited by selection bias, institutional bias, or 
referral bias in which the baseline characteristics of the patients who present at 
that institution may not be representative of the entire population of patients with 
subglottic cancer, thus the results may not be generalizable. Most studies did not 
report whether all sequential patients were included in their results. 
V. Clinically important outcomes: As outlined above, one of the most important 
outcomes in laryngeal cancer is “laryngectomy-free survival”. To determine 
whether organ (laryngeal) preservation protocols are effective, the composite 
outcome of laryngectomy-free survival must be reported.  
 
4.2 Relevance of Proposed Research 
Although patients who present with subglottic cancer are rare, having accurate survival 
and prognostic data can help with future treatment decision making as well as with 
patient counseling. Given the low numbers of patients with subglottic cancer, treatment 
protocols from patients with laryngeal cancer in other subsites are being applied to 
patients with subglottic cancer. It is important to ensure that we are aware of the 
survival outcomes for patients with subglottic cancer so that we know if improvements in 




to provide needed information about the survival outcomes of patients with subglottic 
carcinoma in the province of Ontario, Canada. The results will also add to the literature 
at large to provide results on the clinically important outcome of laryngectomy-free 
survival on a population level for patients with subglottic carcinoma.  
   
4.3  Assessment of Possible Research Methodologies 
Randomized control trials (RCTs) are generally considered to be the gold standard in 
evidence-based medicine (EBM). A properly designed large RCT allows researchers to 
compare different therapies, while also minimizing confounding from known and 
unknown confounding variables, which are, usually, balanced across two comparative 
groups following randomization. In oncology, RCTs have advanced the care for patients 
by enabling researchers to answer important questions regarding the efficacy of a 
therapy aimed at driving evidence based decision-making.  
 
RCTs do have limitations however. They can be costly to conduct, may require a large 
number of patients to detect small differences in treatment effect, may take a long time 
to finish depending on patient accrual time and the outcomes investigated, and tend to 
have participating patients who are highly selected and do not represent actual clinical 
populations.[151] Due to these limitations, obtaining evidence through other means, 
such as prospective multi-institutional observational studies, may be required.  
 
Although RCTs have long been considered the first choice for evidence generation in 




estimates of risk, there are many instances where results from experimental studies are 
not indicative of real-life application. Observational studies are a source of evidence 
generation that can answer research questions that are less suited for an RCT. For 
example, observational studies can be more appropriate in instances of rare disease, 
when it is unethical to randomly assign the intervention of interest, when it is impossible 
to randomize the factor of interest, or when it is impractical to assign the 
intervention.[151] Additionally, observational studies have the advantage of being less 
costly and labor intensive to carry out than an experimental study and can provide initial 
evidence to support the implementation of a future RCT.[152] 
 
Observational studies play an important role in evidence-based medicine in the 
generation of primary evidence for practice guideline construction and policy driven 
decision-making. The use of administrative data in observational studies has the 
advantage of being inexpensive to use, contains information on very large populations 
and provides information on outcomes requiring a longer follow-up time.[153] However, 
limitations in observational studies exist, which if not properly accounted for can lead to 
erroneous results. The inability to randomly allocate patients to different therapies can 
lead to confounding, which occurs when there are imbalances between confounding 
variables among patient groups.[153]  A confounding variable is defined as a variable 
that is associated with the primary variable of interest (independent variable) and 
associated with the outcome of interest (dependent variable), but is not an intermediate 
variable in the causal pathway between the independent variable and dependent 




confounders has the potential to change the magnitude or even direction of an 
estimated treatment effect. However, a properly designed study using appropriate 
analytical methods can help reduce inaccurate estimates of the association between 
treatment and outcome that is caused by measured confounding variables.[153] 
 
4.4 Our Research Approach 
To determine whether primary radiation or primary surgery is superior for the treatment 
of subglottic carcinoma, the highest level of evidence would be achieved by a 
randomized clinical trial (RCT) comparing patients with subglottic carcinoma treated 
with radiation (with or without chemotherapy) versus primary surgery (laryngectomy). 
The small numbers of patients diagnosed every year with subglottic cancer (76 patients 
diagnosed in the province of Ontario from 1995-2007)[36] and the high cost associated 
with running an RCT render this study design infeasible. For these reasons, we 
conducted a population-based retrospective observational study to determine the 
survival outcomes of patients with this disease.  
 
4.4.1 Secular Trends 
Secular trends are defined as “the changing pattern of disease in populations over 
time”.[155] Analyses for secular trends are useful for rapidly providing evidence for 
hypothesis generation and preliminary research.  Possible reasons for changes in 
trends over time can be classified as artifactual, and real. Artifactual changes may be 
errors in the numerator due to changes in the recognition of disease, changes in the 




may also be errors in the denomination due to error in the enumeration of the 
population. Real changes include changes in age distribution of the population, changes 
in survivorship and changes in incidence of disease resulting from genetic factors and 
environmental factors. Secular trends can be used to determine if an intervention such 
as a change in treatment practice has resulted in better or worse survival over time. 
Interpreting secular trends requires care. Outcomes are compared over several years or 
decades, such observations are especially susceptible to biased conclusions. Threats to 
correct interpretation of secular trends include changes in disease definitions, altered 
categorization of disease, establishment of new disease entities, changes in disease 
outcomes, more accurate diagnostic techniques, and an updated understanding of 
disease etiology. Furthermore, demographic changes, changes in living conditions, 
lifestyle changes, landscape changes, catastrophes and migration can also impact 
interpretation of secular trends.  
 
The limitations associated with using secular trends for this project are as follow: 
I. Changes in the patients’ susceptibility to disease would diminish the number 
of cases of the disease. For laryngeal cancer reduced susceptibility would be 
the declining incidence in smoking over time, a known risk factor for laryngeal 
cancer.  
II. Change in disease definitions. As mentioned previously the anatomic 
boundary of the subglottis has been the source of much controversy. This 
may have resulted in misdiagnosis of patients with subglottic cancer as glottis 




III. Secular trends do not capture the point that the incidence of the disease or 
treatment of the disease changes. The publication of the RTOG-9111 study in 
2003 resulted in most centers moving away from primary laryngectomy for the 
treatment of advanced stage laryngeal cancer in favor of organ preservation 
protocols combing chemotherapy with radiation with the goal of laryngeal 
preservation.[74] Secular trends studies will not capture the time point where 
treatment practice changed rather a trend over time may be observed.   
IV. “Ecologic fallacy”- a term used to represent the fact that associations 
observed at the level of the group or population may not represent the 
association at the individual level. Analyses of secular tends are unable to 
differentiate which factor is likely to be the true cause of the outcome of 
interest and establish a causal relationship between the exposure and 
outcome of interest on an individual level.  
V. Changes in diagnostic methods. In the setting of subglottic carcinoma, 
improved CT scanners and MRI scanner may have resulted in more patients 
being diagnosed with advanced stage disease over time (due to greater pick 
up of cartilage invasion) resulting in more patients being treated with dual 
modality treatment (surgery followed by radiation or a combination of radiation 
and chemotherapy).   
 
4.4.2 Regression-Based Modeling 
Multivariable regression modeling is a traditional analytical approach used in 




allows investigators to estimate the association between a treatment and outcome, 
while keeping other covariates in the model constant.[154] As long as the number of 
outcomes of interest in the study sample is large, regression modeling using either, 
linear regression for continuous outcomes, or logistic regression for binary outcomes, 
has the advantage of adjusting for a substantial number of confounding variables. 
However, there are some limitations to regression-based models, some of which 
include: they do not account for confounders which are not included in the model, they 
are unable to provide accurate estimates of association when there is insufficient 
overlap among covariates between treatment groups, and they are bound by the 
assumptions of the regression model chosen.[156]  
 
4.4.3 Strengths of Ontario’s Health Administrative Data 
The Institute for Clinical and Evaluative Sciences (ICES) is a not for profit organization 
which houses the large population-based databases in Ontario, Canada. Ontario 
currently has approximately 13 million residents who have universal access to hospital 
and physicians care. The organization links the databases using personal health 
number such that demographic, socioeconomic, treatment and outcome data is 
available for individual patient populations. ICES captures all residents of Ontario with 
minimal selection bias and loss to follow-up. Access to these linked databases allows 
researchers to study rare populations of patients with high statistical power and low 
cost. Compared to large population-based databases in the United states (SEER and 
NCDB), the main advantage of ICES is that it has physician billing codes and robust 




This data is thought to be reliable given the financial remuneration for submission and 
encoding of the data. We have used these data sources to assess the secular trends of 
laryngeal cancer sites previously.[36]  
 
4.4.4 Limitations of Ontario’s Health Administrative Data 
In cancer research the main limitations of using administrative data in Ontario are the 
lack of staging and treatment details. Staging data is available in Ontario from 2005 
onwards thus limiting the analysis that can be performed prior to 2005. Additionally, 
nuances about the patient presentation such as airway obstruction, feeding limitations, 
and ECOG score are not captured by the databases. Some administrative data codes 
have been validated for use in research, but the vast majority have not, therefore coding 
errors may occur. This is a consideration in the classification of subglottic cancer as 
some patients may have been inappropriately misclassified as subglottic but were glottic 
cancer with subglottic extension.  
 
4.5 Population-based Survival Outcomes Analyses Considerations  
4.5.1 Strengths of Population-based Survival Outcomes Analysis 
There are several strengths associated with using population databases for survival 
analysis. In the province of Ontario, there is very little migration out of the province, 
therefore, loss to follow-up or the requirement to censor for loss to follow-up is not a 
major concern. Vital statistics are reliably captured, and we can be certain that the 





4.5.2 Limitations of Population-based Survival Outcomes Analysis 
There are several analytic challenges to consider when conducting population-based 
survival outcome analyses in oncology patients. First, while the outcome of mortality is 
reliably captured the cause of death is not. Using ICES data, the outcome of overall 
survival or mortality is reliable however, the outcome of disease-specific mortality is not. 
Patients with laryngeal cancer often have several competing risks. Second, OHIP billing 
codes for surgical treatment are reliable however, billing codes for radiation and 
chemotherapy are not reliable. Therefore, several assumptions about treatment are 
usually made. We assume that patients who have no billing record for surgery were 
treated with radiation, however some of these patients may have received no treatment. 
Third, there are several confounders that must be adjusted for in survival analysis of 
patients with laryngeal cancer. Data on some of these confounders is available but 
confounders such as stage of disease is variable and there is no smoking or alcohol use 
data in ICES. Fourth, while reporting of pathology to Ontario Cancer Registry is reliable 
as there is mandatory reporting of all pathology specimens, reporting of the site of the 
cancer may not be accurate.  
 
4.6 Rationale 
Given the current state of the literature, the study conducted here is novel and meets an 
information need. We have considered other study methods to determine the survival 
outcomes of patient with subglottic carcinoma but given the low incidence, a 
retrospective population-based design is the best available. We have considered the 




selection bias with institutional reviews administrative data that captures all patients 
diagnosed with subglottic cancer in the province of Ontario will help reduce selection  
bias. The majority of cancer patients in Ontario are treated at a high volume cancer 
centre whereas in other countries, high numbers of patients are treated at low volume 
cancer centres. As well as the methodology of secular trends will allow us to explore 
changes in the survival trends with the introduction of chemotherapy and new 






CHAPTER FIVE: RESEARCH QUESTIONS AND FRAMEWORK 
5.1 RESEARCH QUESTIONS 
5.1.1 Survival Outcomes of Patients with Subglottic Cancer 
Among all patients with a diagnosis of subglottic carcinoma over a 15-year period 
(1995-2009) in the province of Ontario, Canada what is the 5-year overall survival and 
5-year laryngectomy free survival? 
 
Hypothesis: We expect overall survival will be low and similar to population-based 
reports in the literature.[18] We expect laryngectomy-free survival will be lower than 
overall survival and lower to that reported for other subsites of laryngeal cancer (glottis 
and supraglottic).[36]  
 
5.1.2 Secular Trends in Overall Survival and Laryngectomy-free Survival of Patients 
with Subglottic Cancer 
Over the 15-year period (1995-2009) in the province of Ontario, Canada has the 5-year 
overall survival and 5-year laryngectomy-free survival improved in patients with 
subglottic cancer? Is there an association between the introduction of chemotherapy 
protocols in 2003 and improved radiation techniques and secular trends in 
laryngectomy-free survival over the 15-year period from 1995-2009? 
 
Hypothesis: We expect that improved radiation techniques, the addition or 
chemotherapy to radiation protocols, improved perioperative management of patients 




5-year overall survival in patients with subglottic cancer. The RTOG-9111 study 
published in 2003 found that chemotherapy had a survival benefit when used 
concurrently with radiation.[74]  We expect that the laryngectomy-free survival in 
patients treated in era after 2003 will be improved compared to the eras before the 
study was published.  
 
5.1.3 Survival of patients treated with primary surgery versus primary radiation 
Among patients with subglottic cancer in the province of Ontario is primary treatment 
with surgery associated with a better 5-year overall survival than primary treatment with 
radiation (+/- chemotherapy). 
 
Hypothesis: We expect based on previous research on patients with glottic and 
supraglottic cancer that primary treatment with surgery will result in an improved 5-year 
overall survival.  
 
5.2 RESEARCH FRAMEWORK 
In order to address these questions, we conducted a retrospective population-based 
cohort study of all consecutive patients diagnosed in subglottic squamous cell 
carcinoma over a 15-year period (1995-2009) in Ontario, Canada to determine the 5-
year overall survival, 5-year laryngectomy-free survival, secular trends in overall and 
laryngectomy-free survival and to determine if treatment with surgery is associated with 





CHAPTER SIX: PATIENTS AND METHODS 
6.1 Overview of Study Methodology 
We performed a retrospective population-based study to assess the secular trends in 
subglottic squamous cell cancer in Ontario, Canada.  Study conduct and reporting 
follow guidelines (STROBE) for observational studies (Appendix C).[157] The study was 
approved by the Sunnybrook Health Sciences Centre Research Ethics Board according 
to a pre-specified protocol (Appendix D and E). However, numbers of participants were 
suppressed in the case of five or fewer participants (reported as ≤ 5) to comply with 
privacy regulations for minimizing the chance of identification of a study participant. 
 
6.2 Study Population 
Residents of Ontario (2014 population estimate: 13, 678,700)[158] have universal 
access to hospital care and physician services. Encounters are recorded in large 
population-based health care databases, many of which are held at the Institute for 
Clinical Evaluative Sciences (ICES).  
 
6.3 Data Sources 
We used five linked databases accessed through ICES.  
I.  Ontario Cancer Registry (OCR), which records data on all patients with non-skin 




II. Discharge Abstract Databases held by the Canadian Institute for Health 
Information (CIHI-DAD), which records all admissions to hospitals and includes 
information about diagnoses and procedures performed.  
III. Ontario Health Insurance Plan Databases (OHIP), which contains information on 
all fee-for-service physician claims for inpatients and outpatient services.  Each 
claim record include information about the physician, service provided and 
diagnostic information. 
IV. Registered Persons Database (RPDB), which contains vital statistics about all 
permanent residents of Ontario.  
V. National Ambulatory Care Reporting System Database (NACRS), which collects 
data on ambulatory care visits, including day surgery, outpatient clinics, cancer 
clinics, and emergency department visits.  
 
The databases were linked using unique encoded identifiers (encrypted Ontario health 
care numbers that are unique to each resident eligible for health care services paid by 
the government) available starting July 1991, after the assignment of new health care 
numbers in Ontario.  We previously used these data sources to study secular trends in 
other conditions.[36, 161] For the present work, we used the OCR to identify laryngeal 
cancer patients (subsite subglottis), and the CIHI-DAD, NACRS, OHIP and RPDB 
databases to define patient’s characteristics, baseline comorbidities, and patient 
outcomes. Diagnoses were identified using International Classification of Disease, 9th 
revision (pre-2002) and 10th revision (post-2002) codes, while procedures were 




Procedures (pre-2002) and the Canadian Classification of Health Interventions (post-
2002) codes. 
 
The Canadian Institute for Health Information Discharge Abstract Database, Same Day 
Surgery and National Ambulatory Care Reporting System (CIHI-DAD, SDS, NACRS) 
databases collect demographic, diagnostic and procedural variable for inpatients, 
emergency department and outpatient visits. Diagnostic and inpatient procedural codes 
used the 9th version of the International Classification of Disease system (ICD-9) prior to 
2002 and the 10th version (ICD-10) thereafter.  
 
The Ontario Health Insurance Plan (OHIP) captures information on inpatients, 
outpatient and laboratory services based on billing claims from Ontario physicians. We 
used OHIP diagnostic codes to identify baseline conditions and both procedural and 
diagnostic codes to define our outcomes.  
 
The Registered Persons Database (RPDB) captures demographic information on 
Ontario residents including their sex, date of birth, postal code and vital status. We used 
the RPDB to ascertain baseline demographics, exclusion criteria and potential 
confounders.  
 
6.4  Patients 
All patients diagnosed with laryngeal cancer and SCC on histology during 1995 – 2009 




complete 3-year look-back for baseline comorbidities, cohort accrual began on January 
1, 1995. We restricted our cohort to patients who were residents of Ontario and who 
had a histologic diagnosis of squamous cell carcinoma. A prior validation study found a 
sensitivity of 89.8% and a positive predictive value of 96.8% for the diagnostic code for 
laryngeal cancer in the registry compared with a clinical database.[162] The date of the 
laryngeal cancer diagnosis (“index date”) served as the start time for follow-up. 
 
Patients were further divided into supraglottic, glottic and subglottic cancers. Staging 
data were available only for the subpopulation diagnosed from 2005 to 2009. Registry 
staging ranged from I to IV and was derived from either the American Joint Committee 
on Cancer staging manual (6th or 7th edition).[5] We classified patients staged I and II 
as “early-stage”. According to both versions of the staging manual, early-stage grouping 
includes only patients with local disease and excludes patients with regional or distant 
metastases. Patients staged III and IV were classified as “advanced-stage”. This group 
included patients with advanced local disease and patients with regional or distant 
metastasis. Patients who underwent laryngectomy within 3 months of the initial 
diagnosis were treated with primary laryngectomy.  We assumed that 3 months would 
allow enough time to capture those patients whose treatment was delayed for other 
medical problems, but it was too soon for radiation failure to be identified (assuming 6-
7-week course of radiation). Those who underwent laryngectomy after 3 months were 
chemo/radio-therapy failures and required a salvage laryngectomy. Those not treated 





6.5  Outcomes 
We categorized the study period into three eras: 1995-1999; 2000-2004; 2005-2009. 
We selected these eras to correspond with the availability of staging data, which 
initiated in 2004; this allowed for division of the cohort into three approximately equal 
periods. We determined 5-year mortality after a subglottic cancer diagnosis for each of 
the three eras and the rate per 100 person years.  We assessed two primary outcomes 
in the 5 years following a new diagnosis of laryngeal cancer: overall survival and 
laryngectomy-free survival. We defined overall survival as the proportion of patients 
alive 5 years from the date of diagnosis censoring for patients who were lost to follow-
up before 5 years.  Laryngectomy-free survival as the proportion of patients alive 5 
years from the date of diagnosis with an intact larynx, censoring for patients who were 
lost to follow-up. Deaths (including out-of-hospital mortality) are well ascertained in the 
RPDB, which provides accurate mortality data for all Ontario residents.[163]   
 
6.6 Statistical Analysis 
6.6.1 Cohort demographics 
Patients with a diagnosis of subglottic cancer were divided into three eras: 1995-1999; 
2000-2004; 2005-2009. For each era and for the 15-year time period the mean age with 
standard deviation, age (≤64, >65), sex, Charlson comorbidity group (0, 1 , ≥2), and 
treatment (laryngectomy, salvage laryngectomy and radiation) were reported. To 
determine whether there was a difference in demographic characteristics among the 





6.6.2 Survival Outcomes of Patients with Subglottic Cancer 
We determined the crude 5-year mortality of patients after a subglottic cancer diagnosis 
and calculated the rate per 100py. Kaplan-Meier plots adjusting for age (≤64, >65), 
Charlson comorbidity (0, 1, ≥2) and sex (male/female) were generated for both 5-year 
overall survival and 5-year laryngectomy free survival.  
 
6.6.3 Secular Trends in Overall Survival and Laryngectomy-free Survival of Patients 
with Subglottic Cancer 
We divided patients into three eras, and generated Kaplan-Meier plots for both 5-year 
overall survival and 5-year laryngectomy free survival. We used the log rank test to 
determine whether there was a difference in survival amongst the three eras for each 
outcome. 
 
6.6.4 Survival of patients treated with primary surgery versus primary radiation 
We used the PHREG Procedure in SAS to perform a Cox proportional-hazards 
regression model to investigate the association between treatment with surgery versus 
radiation and survival adjusting for the influence of potential confounders (age, sex and 





SAS software package (version 9.3: SAS Institute, Cary, NC, USA) was used for all 







CHAPTER SEVEN: RESULTS 
7.1 Cohort Description and Demographics 
From 1995 – 2009, a total of 4,977 patients with a diagnosis of laryngeal cancer were 
identified. Out of those, 50 patients were excluded for insufficient information leaving 
4,927 patients; 1371 (27.83%) were diagnosed supraglottic cancer, 3201 (64.97%) with 
glottic cancer and 89 (1.81%) with subglottic cancer (Figure 3). 
 
Out of 89 patients with subglottic cancer, 31 patients were diagnosed between 1995 – 
1999, 31 patients were diagnosed between 2000 – 2004 and 27 patients were 
diagnosed between 2005 – 2009. Baseline characteristics are reported in Table 7. 
Mean age at the time of diagnosis was 68 years and 68 (76.4%) patients were males. A 
total of 13 (14.6%) patients underwent primary laryngectomy, 15 (16.9%) patients 
underwent salvage laryngectomy and 61 (68.5%) patients did not undergo laryngectomy 
within 5 years of diagnosis. There was no difference in the number of patients who 






Figure 3 Selection of patients for subglottic cancer cohort 
 
 
















» Invalid provincial health care 





Year of Diagnosis 1995-2009 
(N=89, %) 
P value‡ 
Age Mean (SD) 
        <65 






Sex Men  0.417 
        Male 68 (76.4)  
       Female 21 (23.6)  
Charlson Comorbidity Index  0.826 
     0 19 (21.3)  
     1 ≤5 (4.5)  
     ≥2 8 (9.0)  
     N/A 58 (65.2)  
Stage* 
     I/II 
     III/IV 
Treatment 
   Primary Laryngectomy** 














   Salvage Laryngectomy ┼┼ 15 (16.9%) 
*Stage: Staging information was only available for 2005-2009 
**Primary laryngectomy was defined as those patients undergoing laryngectomy within 
3 months of the date of diagnosis 
┼Radiation codes were not available, therefore we assumed that if patients did not have 
a primary laryngectomy they were treated with radiation however patients who received 
no treatment may also have been included in this group 
┼┼Salvage laryngectomy was defined as those patients undergoing laryngectomy after 3 
months of date of diagnosis 
‡Kruskal-Wallis test used to compare patient demographics amongst patients in three 
eras (1995-1999, 2000-2004, 2005-2009). Data not shown for privacy reasons as 
several cells were ≤5.  
 
7.2 Survival Outcomes of Patients with Subglottic Carcinoma 
Table 11 outlines 5-year mortality after diagnosis of subglottic cancer. Five-year 
mortality was 58.06% (18/31) from 1995 – 1999, 41.94% (13/31) from 2000 – 2004 
59.26% (16/27) from 2005 – 2009. For the entire cohort, 5-year overall survival was 
47.2%, and 5–year laryngectomy-free survival was 31.5% (Figures 4 and 5). 
 









Rate per 100 person 
years 
1995-1999 31 18 (58.1%) 19 




2005-2009  27 16 (59.3%) 20 
 
 
Figure 4: Kaplan Meier plot depicting the five-year laryngectomy free survival  
 
 







7.3 Secular trends in Overall Survival and Laryngectomy-free survival in patients with 
subglottic cancer 
Comparing the five year overall and five-year laryngectomy free survival in patients for 
the three eras (1995-1999, 2000-2004, 2005-2009) there was no difference according to 
the log rank test after adjusting for age, sex and Charlson comorbidity status (figure 4 
and 5). 
 
7.4 Survival of patients treated with surgery versus radiation 
Results from the adjusted cox regression model indicate that age (65 years or older vs 
64 years or younger) is a significant predictor of 5-year mortality (Hazard Ratio[HR]: 




observed in 5-year mortality in patients treated with primary laryngectomy versus 
primary radiation (HR: 1.21; 95%CI: 0.55 - 2.67). 
Table 12. Unadjusted hazard ratio of 5-year mortality after diagnosis of subglottic 







Age   
      <65 





Sex   
     Female 1.0 (reference)  
     Male 1.16 0.58-2.34 
Charlson Comorbidity Index 
    0 1.0 (reference)  
    1 





Treatment   









Table 13. Adjusted hazard ratio of 5-year mortality after diagnosis of subglottic 






Age   
      <65 





Sex   
     Female 1.0 (reference)  
     Male 1.26 0.62-2.56 
Charlson Comorbidity Index 
    0 1.0 (reference)  
    1 









     Radiation 










CHAPTER EIGHT: DISCUSSION 
8.1 Summary of Findings in Survival of Subglottic Cancer 
In the Canadian province of Ontario, subglottic squamous cell carcinoma represented 
1.8% of all new diagnoses of laryngeal cancer from 1995-2009.  The 5-year overall 
survival was 47.3% compared to 57.4%  for the other laryngeal subsites.[36] Over this 
15 year period, we observed no improvement in overall survival or laryngectomy-free 
survival. Furthermore, we found no difference in survival comparing patients treated 
with primary laryngectomy versus radiotherapy. 
 
8.2 Subglottic Carcinoma Characteristics 
The demographic characteristics of the patients in our study are consistent with that 
reported in other studies.[6, 15, 36, 131] Subglottic carcinoma in our cohort represented 
1.8% of all laryngeal squamous cell carcinoma. Other studies have found that this 
incidence ranges from 1.0-8.7% of laryngeal SCC, although the majority of studies 
report a range from 1-1.6%.[1, 6, 15]  Variability in the definition of primary subglottic 
cancer over time and inclusion of other histologic cancers in the definition of subglottic 
cancer is likely the reason for the discrepancy in incidence reported in this study 
compared to other series.[1, 13, 20, 164] 
 
Primary subglottic carcinoma is usually asymptomatic early in the disease process and 
traditionally thought to present in advanced stage (50-64% of patients).[6, 18, 19, 165] 




stage and advanced stage disease. The small number of patients in our series and lack 
of staging information prior to 2005 likely accounts for this variability in stage 
presentation. The largest reported study of patients with subglottic squamous cell 
carcinoma demonstrated a 58.4% (219/375) rate of advanced stage presentation.[18] 
Taken together, this data indicated that patients are slightly more likely to present with 
advanced stage disease than early stage disease. 
 
8.3 Subglottic Carcinoma Treatment 
The treatment options for primary subglottic carcinoma include surgery (laryngectomy or 
partial laryngectomy), radiation (+/-chemotherapy) or combination therapy.  Direct 
extralaryngeal extension, a circumferential pattern of intraluminal spread and cartilage 
invasion result in few patients being candidates for partial laryngectomy as primary 
treatment.[120]  With the exception of few patients undergoing partial- or hemi-
laryngectomy, the majority of the patients in other studies underwent total laryngectomy 
(Table 11). There was significant variability in other studies with respect to primary 
treatment administered (Table 11). Some authors treated patients with primary 
surgery[2, 18, 131, 135] while others treated most patients with primary radiotherapy[12, 
15, 20, 71, 138]. Furthermore, the indications for combined modality treatment, adjuvant 
radiation and salvage laryngectomy were often not reported.  
 
In our study, 13 (14.6%) patients underwent primary laryngectomy.  Other reports in the 
literature demonstrate 31-81% of patients treated with primary total laryngectomy and 




determine whether any patients had partial laryngeal surgery in our cohort. In our study, 
68.5% of the patients underwent non-surgical management. Other studies reported 12-
100% of patients treated with primary radiotherapy.[4, 12, 15, 19, 20, 71, 131] We did 
not have access to radiation or chemotherapy billing codes, therefore we assumed that 
if patients did not have a primary laryngectomy they were treated with radiation, 
however some of these patients may have been treated with palliative intent. Our 
reported rate of salvage laryngectomy was 24.6%, however this number may be larger 
as some of the patients in our denominator may have been palliated. It remains unclear 
from our data and other studies what proportion of patients treated with primary 
radiation require salvage laryngectomy and whether organ-preservation protocols 
improve laryngectomy-free survival. 
 
8.4 Survival Outcomes 
We reported 5-year overall survival of 47.2%for all patients with a diagnosis of subglottic 
SCC. Previous studies have reported 5-year overall survival ranging from 25-80% 
(Tables 8 and 9). Some have suggested that a higher rate of local recurrence 
particularly at the peristomal region or a high rate of distant metastatic spread up to 
32% is responsible for the poor overall survival, however the data is unclear.[13]  
Previous studies (Tables 8 and 9) suggest that combined modality treatment either 
surgery plus radiation, chemotherapy plus radiation or radiation followed by salvage 
surgery offers a survival benefit however, the small sample sizes prevent definitive 




received combined modality treatment due to limitations of our databases. Our results 
do however suggest that there may be no survival benefit with primary laryngectomy.   
 
We demonstrated no change in overall survival or laryngectomy free survival from 1995-
2009 (Figures 4 and 5).  These results are consistent with previous work by our group 
and others demonstrating no change in overall survival in patients with glottic and 
supraglottic carcinomas.[35, 36, 166, 167] Although large randomized trials have 
demonstrated an improved laryngectomy-free survival for patients with glottic and 
supraglottic carcinoma treated with concurrent chemoradiation, this benefit has not 
been demonstrated in population-based studies.[35, 36, 166] The reasons for this are 
unknown but may be related to patient selection for laryngeal preservation protocols. 
Additionally, the difficulty in defining primary subglottic carcinoma versus glottic 
carcinoma with subglottic extension as well as the evolving definition of the superior 
boundary of the subglottis may have influenced survival trends over the study period.   
 
8.5 Strengths and Limitations 
To our knowledge, this is largest study reported in the literature on the outcome of 
laryngectomy-free survival in patients with subglottic carcinoma.  Our survival outcome 
is robust, accounting for all patients with a diagnosis of subglottic carcinoma in the 
province of Ontario, Canada. That is, there is no selection bias which is inherent to 
institutional reviews of survival outcomes. Procedural and diagnostic codes were well-
documented.[162] Our study has limitations. We only had T-stage and N-stage 




Furthermore, disease specific survival was not calculated because cause of death has a 
low sensitivity in cancer registries and population databases. We assumed that patients 
who did not receive a primary laryngectomy were treated with primary radiation. Some 
of these patients may have been treated with palliative intent or they may not have 




Subglottic carcinoma has a low incidence and has a poor prognosis compared to other 
laryngeal cancer subsites. The reason for poor overall survival in patients with this 
subsite of laryngeal cancer is unknown but does not appear to be associated with 
advanced stage at presentation. Overall there was no difference in 5-year mortality rate 
between patients treated with primary laryngectomy and those treated without 
laryngectomy. Thus, laryngeal preservation therapy may be considered as a primary 
option for suitable patients. More research is needed to determine which patients are 
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Appendix A. Literature Review Search Strategy 
To collect all studies related to subglottic cancer, we searched MEDLINE (January 1960 
to September 2020), EMBASE January 1947 to September 2020, and CINAHL (1981-
2020). Reference lists of all included studies were also manually searched for additional 
reports. The following key words were used for the comprehensive search: cancer, 
carcinoma, malignancy, squamous cell cancer, subglotti*. For MEDLINE the search 
strategy was (("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All 
Fields]) OR ("carcinoma"[MeSH Terms] OR "carcinoma"[All Fields]) OR 
("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "malignancy"[All Fields])) 
AND (subglottic[All Fields] OR subglottica[All Fields] OR subglottical[All Fields] OR 
subglottically[All Fields] OR subglottice[All Fields] OR subglottictracheal[All Fields] OR 
subglottid[All Fields] OR subglottie[All Fields] OR subglottig[All Fields] OR subglottik[All 
Fields] OR subglottis[All Fields] OR subglottisch[All Fields] OR subglottische[All Fields] 
OR subglottischen[All Fields] OR subglottischer[All Fields] OR subglottisches[All Fields] 
OR subglottiscope[All Fields] OR subglottiscopes[All Fields] OR subglottises[All Fields] 
OR subglottisk[All Fields] OR subglottiske[All Fields]) with limits human and English, 
result 940 titles. For EMBASE the search strategy was (subglottic*.mp AND (cancer.mp 
or malignant neoplasm/)) limits English and humans results 618 titles. We search 
CINAHL for “subglottic*” and retrieved 319 results from 1981-2020, using limits of 





Appendix B. NewCastle-Ottawa Quality Assessment Scale for Cohort Studies 
 
Note: A study can be awarded a maximum of one star for each numbered item within 




1) Representativeness of the exposed cohort 
a) truly representative of the average  (describe) in the community * 
b) somewhat representative of the average  in the community * 
c) selected group of users eg nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non-exposed cohort 
a) drawn from the same community as the exposed cohort * 
b) drawn from a different  source 
c) no description of the derivation of the non-exposed  cohort 
3) Ascertainment of exposure 
a) secure record (eg surgical records) * 
b) structured interview * 
c) written self- report 
d) no description 
4) Demonstration that outcome of interest was not present at start of study 
a) yes * 
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for  (select the most important factor) * 
b) study controls for any additional factor * (This criteria could be modified to 
indicate specific control for a second important factor.) 
Outcome 
1) Assessment  of outcome 
a) independent blind assessment * 
b) record linkage * 
c) self report 
d) no description 
2) Was follow-up long enough for outcomes to  occur 





3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for * 
b) subjects lost to follow up unlikely to introduce bias - small number lost - > 
 % (select an adequate %) follow up, or description provided of those lost) 
* 
c) follow up rate <  % (select an adequate %) and no description of those lost 






Appendix C. Checklist of Recommendations for Reporting of Observational Studies 




 Location  
 Title and abstract 1 (a) Indicate the study’s design with a commonly used 
term in the title or the abstract 
 1  
(b) Provide in the abstract an informative and 
balanced summary of what was done and what was 
found 
 2  
Introduction    
Background/rationale 2 Explain the scientific background and rationale for 
the investigation being reported 
 84  
Objectives 3 State specific objectives, including any prespecified 
hypotheses 
 86  
Methods    
Study design 4 Present key elements of study design early in the 
paper 
 88  
Setting 5 Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-up, 
and data collection 
 90  
Participants 6 (a) Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe 
methods of follow-up 
 92  
(b) For matched studies, give matching criteria and 
number of exposed and unexposed 
 N/A  
Variables 7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
 93  
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data 
and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one group 
 88  
Bias 9 Describe any efforts to address potential sources of 
bias 
 92  




Quantitative variables 11 Explain how quantitative variables were handled in 
the analyses. If applicable, describe which groupings 
were chosen and why 
 92  
Statistical methods 12 (a) Describe all statistical methods, including those 
used to control for confounding 
 92  
(b) Describe any methods used to examine 
subgroups and interactions 
 92  
(c) Explain how missing data were addressed  92  
(d) If applicable, explain how loss to follow-up was 
addressed 
 N/A  
(e) Describe any sensitivity analyses    
Results    
Participants 13* (a) Report numbers of individuals at each stage of 
study—eg numbers potentially eligible, examined for 
eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed 
 95  
(b) Give reasons for non-participation at each stage  96  
(c) Consider use of a flow diagram  96  
Descriptive data 14* (a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on 
exposures and potential confounders 
 96  
(b) Indicate number of participants with missing data 
for each variable of interest 
 96  
(c) Summarise follow-up time (eg, average and total 
amount) 
 97  
Outcome data 15* Report numbers of outcome events or summary 
measures over time 
 97  
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision 
(eg, 95% confidence interval). Make clear which 
confounders were adjusted for and why they were 
included 
 101  
(b) Report category boundaries when continuous 
variables were categorized 
 98  
(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful time 
period 
 N/A  
Other analyses 17 Report other analyses done—eg analyses of 
subgroups and interactions, and sensitivity analyses 
 102  
Discussion    
Key results 18 Summarise key results with reference to study 
objectives 




Limitations 19 Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss both 
direction and magnitude of any potential bias 
 107  
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
 106  
Generalisability 21 Discuss the generalisability (external validity) of the 
study results 
 106  
Other information    
Funding 22 Give the source of funding and the role of the funders 
for the present study and, if applicable, for the 
original study on which the present article is based 
 5  
 







Appendix D: Secular Trends in Laryngeal Carcinoma: Incidence, 
Treatment and Survival 
Number of 
Study 
2014 0906 036 000 
Team 
Contacts 
S. Danielle MacNeil 
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Stephen Hall 
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April 23, 2013 (DM) 
April 3, 2013 (DM) 
March 28, 2013 (DM) 
March 19, 2013 (AG, JF, SS) 
March 18, 2013 (DM) 
May 30, 2013 (DM) 
June 10, 2013 (DM) 
June 12, 2013 (DM) 
June 19, 2013 (DM) 
July 5, 2013 (DM) 






Objectives of this Project (Incidence and Trends) 
To assess the secular (annual) trends in incidence of laryngeal carcinoma.  
To assess the secular (annual) trends in treatment of laryngeal carcinoma. 
To assess secular  (annual) trends in 2, 3 and 5 year survival laryngeal 
carcinoma. 
To determine if there is improved 2, 3 and 5 year survival and laryngectomy free 
survival for patients with laryngeal cancer who have been treated with 
chemotherapy and radiotherapy versus radiation alone 
 
Hypotheses:   
The incidence of laryngeal carcinoma will have decreased over the past 19 
years, secondary to the decreased rate of smoking. The treatment practices will 
have shifted from primary radiotherapy and primary surgery to primary 
chemoradiotherapy and transoral laser surgery. There will be improved survival 
for patients with advanced stage disease treated with primary surgery.  
 
Main population of interest:   
Patients 18 years of age and older with a diagnosis of laryngeal carcinoma, treated with 
surgery, radiation and/or chemotherapy in the province of Ontario from 1991 to 2010. 
 
Main outcomes of interest:   
Outcomes are incidence (number of patients diagnosed with laryngeal cancer per year 




January 1, 1991 to December 31, 2010.  
Beginning of Accrual Period: January 1, 1991 





The last day of accrual period is December 31, 2010.  
Databases 
Used RPDB, CIHI-DAD, OHIP, OCR, ODD, HYPERTENSION 
Defining the Cohort 











▪ Begin with patients who have a diagnosis of laryngeal carcinoma 
according to OCR from January 1, 1991 to December 31, 2010 (see 





• All patients with diagnosis of laryngeal carcinoma 
 
• Squamous cell histology 
 
• Begin with all patients in OCR with diagnosis of laryngeal carcinoma 
during accrual period 
 




▪ Patients with invalid or missing IKN, age, or sex (data-cleaning step) 
 
▪ Patients that are non-Ontario residents (data-cleaning step) 
 
▪ Death on or before index date 













▪ Assessed at the time of index date, sample Table 2 for format 
 
1. Year of Index Date (report calendar year) 
 
2. Gender (female, N(%)) 
 
3. Age at index date 
▪ Mean age (years) 
▪ Median age (years) 
▪ Standard deviation for age (years) 
▪ Age categories (crude number) 
▪ <50 years 
▪ 50-59 years 
▪ 60-69 years 
▪ 70-79 years 
▪ >=80 years 
 
4. Socioeconomic status 
• Income quintile, for missing impute as 3 (median income) 
 
5. Residency status, rural or urban (report only categorical number (%)), 
for ‘missing’, code this as urban 
 
6. Cancer treatment centre (report only categorical number (%)) 
 
7. Charlson Comorbidity Index (CCI) 
• Use 5-year look back window to calculate 
• Possible scores are 0, 1, 2, >=3 
• No hospitalization or missing values to be denoted ‘0’ 
 
8. Elixhauser 




• 1991-use DAD for 1 year look back 
• Use 1 year look back 1992-1996 
• Use 5 year look back 1997-2010 
• Record ADG sum as groupings 1-12, 13-20, 20-34 
 
10. Comorbidities 
• Use Appendix C to define comorbidities 
 
11. Previous treatment for Head and Neck Cancer 
• Use 5-year look back window to calculate 
• Number of patients with past history of radiotherapy treatment or 
follow-up in 5 year period prior to index date and diagnosis of head 




• Number of patients with past history of major head and neck cancer 
resection in 5 year period prior to index date and diagnosis of head 
and neck cancer (Appendix B) 
 
12. Tumor stage 
• Crude number stage 1-4 and percent 
 
13. Tumor site (Appendix D) 
 




*crude number and percent of larynx cancer cases reported by age group 










Complete Tables 1 and 2 for feasibility. Once all investigators have signed 
off on Tables 1 and 2 then proceed with remaining tables.  
 
 
1.  Treatment trends (Appendix E) 
▪ For each cancer site as well as for total sample per year determine 
number of patients who received each treatment type 
▪ Group 1 :Laryngectomy, primary treatment based on surgery, no other 
treatments administered for 5 years post surgery 
▪ Group 2: Non-laryngectomy surgery, primary treatment based on surgery, 
no other treatments administered for 5 years post surgery 
▪ Group 3: Open surgery followed by Radiation, surgery and radiation 
therapy administered within 4 months 
▪ Group 4: Endoscopic surgery followed by radiation, endoscopic surgery 
followed by radiation administered within 4 months 
▪ Group 5a: Open Surgery followed by radiation, radiation therapy 
administered from 4 months to 5 years after surgery 
▪ Group 5b: Endoscopic surgery followed by radiation, radiation therapy 
administered from 4 months to 5 years after surgery 
▪ Group 6: Open surgery followed by Chemoradiation, surgery followed by 
chemotherapy and radiation therapy both administered within 4 months of 
surgery 
▪ Group 7: Endoscopic surgery followed by chemoradiation, endoscopic 
surgery followed by chemotherapy and radiation both administered within 
4 months. 
▪ Group 8a: Open Surgery followed by chemoradiation, chemoradiation 
administered from 4 months to 5 years after surgery 
▪ Group 8b: Endoscopic surgery followed by chemoradiation, 
chemoradiation administered from 4 months to 5 years after surgery 
▪ Group 9: Radiotherapy, primary treatment based on radiotherapy without 
chemotherapy, no other treatments administered for 5 years post radiation 
▪ Group 10: Concurrent Chemotherapy and Radiotherapy, primary 
treatment based on radiotherapy with chemotherapy, chemotherapy 
followed by radiation administered within 2 months, no other treatments 
administered for 5 years 
▪ Group 11: Radiotherapy followed by surgery, radiotherapy followed by 
surgery administered within 6 months 
▪ Group 12: Radiotherapy followed by surgery, radiotherapy followed by 
surgery administered 6 months to 5 years after treatment 
▪ Group 13: Concurrent Chemotherapy and radiotherapy followed by 




months, followed by surgery administered within 6 months of last 
treatment 
▪ Group 14: Concurrent chemotherapy and radiotherapy followed by 
surgery, chemotherapy and radiation administered within 2 months, 
followed by surgery administered 6 months to 5 years of last treatment 
▪ Group 15: Chemotherapy only, no other treatment administered within 5 
years 
▪ Group 16: No treatment given or data not available 
 
▪ See Tables 2-7 for format 
 
2. Trends in Surgery (Appendix F)  
▪ For entire cohort of patients 
▪ For each cancer site as well as for total sample per year 
▪ Report number of patients who had OHIP billing code for surgery 
▪ Crude number and percent of procedures per year 
▪ Include procedures that occur on the same day 
▪ For each surgical procedure record if one procedure for each group 
occurred eg. For neck dissection group if R910, R911 and R915 were 
recorded for same patient, this is recorded as one neck dissection 
procedure for that patient (yes/no procedure for each surgical procedure 
group). 
▪ See Tables 8, 9 and 10 for format 
 
3. 5 year overall survival 
 
• Figure 1: K-M 5 year overall survival all laryngeal cancer (3 eras 1991-1996, 
1997-2002, 2003-2007) 
 
• Figure 2: K-M 5 year overall survival glottic cancer (3 eras 1991-1996, 1997-
2002, 2003-2007) 
 
• Figure 3: K-M 5 year overall survival supraglottic cancer (3 eras 1991-1996, 
1997-2002, 2003-2007) 
 
• Calculate survival from date of diagnosis in OCR to date of death in RPDB 
 
4. 5 year Overall Survival Survival for Early and Advanced Stage 
Laryngeal Cancer 
• Figure 4: K-M 5 year overall survival all laryngeal cancer 2004-2007, early stage 
and advanced stage in same graph 
 
• Figure 5: K-M 5 year overall survival glottic cancer 2004-2007, early stage and 





• Figure 6: K-M 5 year overall survival supraglottic cancer 2004-2007, early stage 
and advanced stage in same graph 
 
• Calculate survival from date of diagnosis in OCR to date of death in RPDB 
 
5. 5 year Overall Survival Comparing Treatment Groups 
 
• Figure 7: K-M 5 year overall survival early glottic cancer 2004-2007 for 6 
treatment groups. 
 
• Figure 8: K-M 5 year overall survival advanced stage glottic cancer  2004-2007 
for 6 treatment groups 
 
• Figure 9: K-M 5 year overall survival early stage supraglottic cancer, 2004-2007 
for 6 treatment groups 
 
• Figure 10: K-M 5 year survival advanced stage supraglottic cancer, 2004-2007 for 
6 treatment groups 
 
• Calculate survival from date of diagnosis in OCR to date of death in RPDB 
 
6. 5 year laryngectomy free survival 
 
• Figure 11: K-M 5 year laryngectomy free survival all laryngeal cancer (3 eras 
1991-1996, 1997-2002, 2003-2007) 
 
• Figure 12: K-M 5 year laryngectomy free survival glottic cancer (3 eras 1991-
1996, 1997-2002, 2003-2007) 
 
• Figure 13: K-M 5 year laryngectomy free survival supraglottic cancer (3 eras 
1991-1996, 1997-2002, 2003-2007) 
 
• Calculate survival from date of diagnosis in OCR to date of death in RPDB 
 
▪ Exclude patients who have had a laryngectomy (OHIP code: M081, 
M084, S068;) at any time between date of diagnosis and 5 years 
from date of diagnosis.  
 






• Figure 14: K-M 5 year laryngectomy free survival all laryngeal cancer 2004-2007, 
early stage and advanced stage in same graph 
 
• Figure 15: K-M 5 year laryngectomy free survival glottic cancer 2004-2007, early 
stage and advanced stage in same graph 
 
• Figure 16: K-M 5 year laryngectomy free survival supraglottic cancer 2004-2007, 
early stage and advanced stage in same graph 
 
• Calculate survival from date of diagnosis in OCR to date of death in RPDB 
 
• Exclude patients who have had a laryngectomy (OHIP code: M081, M084, 
S068;) at any time between date of diagnosis and 5 years from date of 
diagnosis.  
 
8. 5 year Laryngectomy free Survival Comparing Treatment Groups 
 
• Figure 17: K-M 5 year laryngectomy free survival early glottic cancer 2004-2007 
for 6 treatment groups. 
 
• Figure 18: K-M 5 year laryngectomy free survival advanced stage glottic cancer  
2004-2007 for 6 treatment groups 
 
• Figure 19: K-M 5 year laryngectomy free survival early stage supraglottic cancer, 
2004-2007 for 6 treatment groups 
 
• Figure 20: K-M 5 year laryngectomy free survival advanced stage supraglottic 
cancer, 2004-2007 for 6 treatment groups 
 
• Calculate survival from date of diagnosis in OCR to date of death in RPDB 
 
• Exclude patients who have had a laryngectomy (OHIP code: M081, M084, 
S068;) at any time between date of diagnosis and 5 years from date of 
diagnosis.  
 
9. Proportional Hazard Analysis of the Predictors of Local Surgery versus 
Radiation Therapy Among Patients with Early-Stage Laryngeal Cancer 
 
• Use data 2004-2010 
• Use only treatment groups “local surgery” and “radiation” 
• Local surgery: groups 2, 5b, 8b 
• Radiation: groups 4, 9, 11, 12 





10. Proportional Hazard Analysis of the Predictors of Laryngectomy 
versus Radiation Therapy Among Patients with Advanced-Stage 
Laryngeal Cancer 
 
▪ Use data 2004-2010 
▪ Use only treatment groups “laryngectomy” and “radiation” 
▪ Laryngectomy: groups 1, 3, 5a, 6, 8a 
▪ Radiation: groups 4, 7, 9, 10, 11, 12, 13, 14 
▪ See table 12 for format 
 
11. Hazard Ratio Model Predicting 5 year overall survival among patients 
with early-stage laryngeal cancer 
 
▪ Use data 2004-2007 
▪ Adjust for age, ADG comorbidity score and year of diagnosis 
▪ See table 13 for format 
 
12. Hazard Ratio Model Predicting 5 year laryngectomy free survival 
among patients with early-stage laryngeal cancer 
 
▪ Use data 2004-2007 
▪ Adjust for age, ADG comorbidity score and year of diagnosis 
▪ See table 14 for format 
 
13. Hazard Ratio Model Predicting 5 year overall survival among patients 
with advanced stage laryngeal cancer 
 
▪ Use data 2004-2007 
▪ Adjust for age, ADGcomorbidity score and year of diagnosis 
▪ See table 15 for format 
 
14. Hazard Ratio Model Predicting 5 year laryngectomy free survival 
among patients with advanced stage laryngeal cancer 
 
▪ Use data 2004-2007 
▪ Adjust for age, ADG comorbidity score and year of diagnosis 

















Appendix B:  Previous History of Head and Neck Radiotherapy or Major Head and Neck 
Surgery for Head and Neck Cancer  
 
 
Appendix C: Comorbidities 
 




Appendix E: Type of treatment 
 
 










Table 1. Cohort selection 
Diagnosis of laryngeal carcinoma (OCR) and histology of squamous cell carcinoma 
(Appendix A) 
N = 
• Invalid IKN, missing date of birth, missing sex N = 
• Non-Ontario Residents N= 
• Death on or before index date N = 
Number of patients in cohort N = 
# of patients with diagnosis of glottic cancer N = 
# of patients with diagnosis of supraglottic cancer N = 
# of patients with diagnosis of subglottic cancer N = 




1997-2002 2003-2010 P value 
Demographics      
Gender N=, (%)     
Female N=, (%)     
Male N=, (%)     
Age      
Median (IQR) Median 
(25th, 75th) 
    
Mean (SD) Mean (SD)     
<50 N=, (%)     
50-59 N=, (%)     
60-69 N=, (%)     
70-79 N=, (%)     
>=80 N=, (%)     
Socioeconomic status      
Low       
2      
3      
4      
High      
Residency Status      
Urban      




    
1      
2      
3      
4      
5      
6      
7      
8      
9      




11      
12      
13      
Co-morbidity (5 years 
prior to index date) 
 




    
Median (IQR) Median 
(25th, 75th) 
    
0      
1      
2      
>=3      
Elihxauser      
0      
1      
2      
3      
>=4      
ADG      
0-12      
13-20      
21-34      


















    
Carotid endarterectomy  
 
 
    
Chronic kidney disease 
 
 
    
Chronic liver disease 
 
 
    
Chronic lung disease 
 
 
    
Coronary artery disease  
 
 




    
Diabetes mellitus  
 
 





















    
Myocardial Infarction (MI) 
 
 














    
Previous Treatment for 
Head and Neck Cancer 
(5years prior to index 
date) 
 
    
Radiation N (%)     
Surgery N (%)     
Tumor Stage (All 
cancers) 
 
    
I      
II      
III      
IV      
Tumor Stage (Glottis)      
I      
II      
III      




    
I      
II      
III      
IV      
Tumor Site      
Glottis      
Supraglottis      










































Laryngectomy Groups 1, 
3, 5a, 8a, 6 
       
Local Surgery Groups 2, 
5b, 8b 
       
Radiation Groups 4, 9, 11, 
12 +radiation (NACRS) 
       
Chemoradiation groups 
7, 10, 13, 14 + 
chemoradiation (NACRS) 
       
Chemotherapy Group 15 
+ chemo (NACRS) 
       
No treatment (group 16) 
       
 





































Laryngectomy Groups 1, 
3, 5a, 8a, 6 
       
Local Surgery Groups 2, 
5b, 8b 
       
Radiation Groups 4, 9, 11, 
12 +radiation (NACRS) 
       
Chemoradiation groups 
7, 10, 13, 14 + 
chemoradiation (NACRS) 
       
Chemotherapy Group 15 
+ chemo (NACRS) 
       
No treatment (group 16) 
       
 
 








































Laryngectomy Groups 1, 
3, 5a, 6, 8a 
       
Local Surgery Groups 2, 
5b, 8b 
       
Radiation Groups 4, 9, 11, 
12 +radiation (NACRS) 
       
Chemoradiation groups 
7, 10, 13, 14 + 
chemoradiation (NACRS) 
       
Chemotherapy Group 15 
+ chemo (NACRS) 
       
No treatment (group 16) 
       
 





































Laryngectomy Groups 1, 
3, 5a, 6, 8a 
       
Local Surgery Groups 2, 
5b, 8b 
       
Radiation Groups 4, 9, 11, 
12 +radiation (NACRS) 
       
Chemoradiation groups 
7, 10, 13, 14 + 
chemoradiation (NACRS) 
       
Chemotherapy Group 15 
+ chemo (NACRS) 
       
No treatment (group 16) 
       
 





































Laryngectomy Groups 1, 
3, 5a, 6, 8a 




Local Surgery Groups 2, 
5b, 8b 
       
Radiation Groups 4, 9, 11, 
12 +radiation (NACRS) 
       
Chemoradiation groups 
7, 10, 13, 14 + 
chemoradiation (NACRS) 
       
Chemotherapy Group 15 
+ chemo (NACRS) 
       
No treatment (group 16) 
       
 





































Laryngectomy Groups 1, 
3, 5a, 6, 8b 
       
Local Surgery Groups 2, 
5b, 8b 
       
Radiation Groups 4, 9, 11, 
12 +radiation (NACRS) 
       
Chemoradiation groups 
7, 10, 13, 14 + 
chemoradiation (NACRS) 
       
Chemotherapy Group 15 
+ chemo (NACRS) 
       
No treatment (group 16) 
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Figure 1: K-M 5 year overall survival all laryngeal cancer (3 eras 1991-1996, 1997-2002, 2003-2007) 
 
Figure 2: K-M 5 year overall survival glottic cancer (3 eras 1991-1996, 1997-2002, 2003-2007) 
 
Figure 3: K-M 5 year overall survival supraglottic cancer (3 eras 1991-1996, 1997-2002, 2003-2007) 
 
Figure 4: K-M 5 year overall survival all laryngeal cancer 2004-2007, early stage and advanced stage in 
same graph 
 
Figure 5: K-M 5 year overall survival glottic cancer 2004-2007, early stage and advanced stage in same 
graph 
 
Figure 6: K-M 5 year overall survival supraglottic cancer 2004-2007, early stage and advanced stage in 
same graph 
 
Figure 7: K-M 5 year overall survival early stage glottic cancer 2004-2007 for 6 treatment groups. 
 
Figure 8: K-M 5 year overall survival advanced stage glottic cancer  2004-2007 for 6 treatment groups 
 
Figure 9: K-M 5 year overall survival early stage supraglottic cancer, 2004-2007 for 6 treatment groups 
 
Figure 10: K-M 5 year overall survival advanced stage supraglottic cancer, 2004-2007 for 6 treatment 
groups 
 
Figure 11: K-M 5 year laryngectomy free survival all laryngeal cancer (3 eras 1991-1996, 1997-2002, 2003-
2007) 
 





Figure 13: K-M 5 year laryngectomy free survival supraglottic cancer (3 eras 1991-1996, 1997-2002, 2003-
2007) 
 
Figure 14: K-M 5 year laryngectomy free survival all laryngeal cancer 2004-2007, early stage and advanced 
stage in same graph 
 
Figure 15: K-M 5 year laryngectomy free survival glottic cancer 2004-2007, early stage and advanced stage 
in same graph 
 
Figure 16: K-M 5 year laryngectomy free survival supraglottic cancer 2004-2007, early stage and advanced 
stage in same graph 
 
Figure 17: K-M 5 year laryngectomy free survival early glottic cancer 2004-2007 for 6 treatment groups. 
 
Figure 18: K-M 5 year laryngectomy free survival advanced stage glottic cancer  2004-2007 for 6 
treatment groups 
 
Figure 19: K-M 5 year laryngectomy free survival early stage supraglottic cancer, 2004-2007 for 6 
treatment groups 
 
Figure 20: K-M 5 year laryngectomy free survival advanced stage supraglottic cancer, 2004-2007 for 6 
treatment groups 
 
Table 11: Predictors of Local Surgery vs Radiation Therapy Among Patients with Early-Stage Laryngeal 
Cancer, 2004-2010 
 
Category OR (95% CI) 
Year of Diagnosis  
     2004  
     2005  
     2006  
     2007  
     2008  
     2009  
     2010  
Gender  
     Male  
     Female  
Age  
     <70  
     >=70  
Socioeconomic Status  
     Low  
     2  
     3  
     4  





     Glottic  
     Supraglottic  
Charlson Comorbidity Index  
     0  
     1  
     2  





Individual Comorbidities  
     Alcoholism  
     Arrhythmia  
     Chronic liver disease  
     Chronic lung disease  
     Coronary Artery Disease  
     Dementia  
     Diabetes  
     Heart Failure  
     Hypertension  
 
 
Table 12: Predictors of Laryngectomy vs Radiation Therapy Among Patients with Advanced-Stage 
Laryngeal Cancer, 2004-2010 
 
Category OR (95% CI) 
Year of Diagnosis  
     2004  
     2005  
     2006  
     2007  
     2008  
     2009  
     2010  
Gender  
     Male  
     Female  
Age  
     <70  
     >=70  
Socioeconomic Status  
     Low  
     2  
     3  




     High  
Subsite  
     Glottic  
     Supraglottic  
Charlson Comorbidity Index  
     0  
     1  
     2  





Individual Comorbidities  
     Alcoholism  
     Arrhythmia  
     Chronic liver disease  
     Chronic lung disease  
     Coronary Artery Disease  
     Dementia  
     Diabetes  
     Heart Failure  
     Hypertension  
 
Table 13: Hazard Ratio Model Predicting 5 year overall survival among patients with early-stage cancer, 
2004-2007 
 
Category OR (95% CI) 
Treatment  
     Local Surgery  
     Radiation  
Subsite  
     Glottic  




Table 14: Hazard Ratio Model Predicting 5 year laryngectomy free survival among patients with early-
stage cancer, 2004-2007 
 
Category OR (95% CI) 
Treatment  
     Local Surgery  
     Radiation  
Subsite  
     Glottic  





Table 15: Hazard Ratio Model Predicting 5 year Overall Survival Among Patients with Advanced-stage 
laryngeal cancer, 2004-2007 
 
Category OR (95% CI) 
Treatment  
     Local Surgery  
     Radiation  
Subsite  
     Glottic  





Table 16: Hazard Ratio Model Predicting 5 year laryngectomy Free Survival Among Patients with 
Advanced-stage laryngeal cancer, 2004-2007 
 
Category OR (95% CI) 
Treatment  
     Local Surgery  
     Radiation  
Subsite  
     Glottic  







Appendix E: ICES Project-Specific Privacy Impact Assessment Form 
INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES 
PROJECT-SPECIFIC PRIVACY IMPACT ASSESSMENT FORM 
(FOR ALL ICES PROJECTS) 
 
A. PROJECT TITLE 





B. THE PROJECT 
  Select the PHIPA Section that applies to this project as the privacy implications are different.  
1) Please indicate below whether this Project falls into PHIPA Section 45i and/or 45ii  
       OR Section 44(iii). (see “Completing PIAs” document and/or Reference*) 
Section 45:  
i) The purpose of the project is analysis or compiling statistical information 
related to evaluation, monitoring, planning, resource allocation, service 
delivery and management of the health care system;  
and/or 
















Sec. 45 ii) 
Section 44:  
iii)    Research purpose other than activities listed in Section 45 above 










2) Has an electronic PIA and Proposal been submitted to the Program 






3) Is data planned for use in this project to be linked with other data sets?    
 
4) Is the rationale for the planned data linkage described in the proposal (or 












5) From a Process and/or Technology perspective, is this project : 
• Introducing a novel methodology or direction? 
• Introducing significant changes from an existing project? 
• Implementing a new remote implementation? 









If yes, security 
consultation  
with CISO may 
be of benefit 
for this project 
 






7) If you answered “yes” in question 6, please identify the student’s designation below: 
 
 MSc   PhD             Other ICES@Western Faculty Scholar 
 
8) Name the project participants / staff and provide contact details here.  
      Use pull-down lists under role to describe each person’s activity. 
 
  At least one ICES scientist must be named for all projects as Investigator or Co-investigator. 
  Include affiliations/qualifications for all scientists who are not ICES scientists/adjunct 





NAME / AFFILIATION/ 
QUALIFICATIONS 
ROLE PHONE E-MAIL 
Amit Garg Co-investigator   
Salimah Shariff, PhD Co-investigator   
Stephen Hall, MD, MSc PI   
S. Danielle MacNeil, MD, MSc Co-PI   
John Yoo, MD Co-investigator   
Amardeep Thind, MD, PhD Co-investigator   
Eric Winquist, MD, MSc Co-investigator   
Jamie Fleet, BSc Co-investigator   
Kuan Liu, MMath PB        
      PI             
      PI             
      PI             
      PI             
      PI             
 
9)  Please name team members who will have access to the individual-level data.  
     (Have you provided names and related qualifications as requested above?) 
 






10)  What types of data are being used? (check all that apply)  
     Identify those, which are being linked to administrative datasets. 
 
Type To be linked 
  ICES Administrative Data  
  Survey  
  Registry  
  Primary clinical  
  Chart abstraction  
  Electronic Health Record  
  Web-based data collection  
  Other: (Please indicate below)                                                              
      
 
11) What databases are being used? (check all that apply) 
Indicate dates of data to be used. (Note: Year means year for which data is summarized. Fiscal year is 
defined as: 1 April 2008 – 31 March 2009 = fiscal 2008. 
 
Type Fiscal year 
Administrative Databases                                                Year 
  CIHI-DAD 1991                 to  2010 
  CIHI-SDS                       to        
  CIHI-NACRS                       to        
  CIHI-CCRS                       to        
  CIHI-NRS                       to        
  ODB                       to        




  HCD                        to        
  LOC                       to        
  OMHRS                       to        
  RPDB N/A 
  CAPE N/A 
  IPDB  N/A 
  CPDB N/A 
  Other  
    
    
 
Composite Databases (i.e., OHIP + CIHI + ODB)                        Day/Month/Yr 
  Asthma*  
  CHF *  
  COPD*  
  Hypertension  
  MOMBaby  
  ODD  
  OMID  
  PIBD*  
  Other  
    
 
* Permission/notification required before use of asterisked datasets. Please contact Director, Information 
Management for details. 
 




  CCN* (approval required)                       to        
  OCR** (approval required) January 1, 1991                 to  December 31, 2010 
  RCSN † (approval required)                       to        
  EFFECT(approval required)                       to        
  OBSP** (approval required)  
  Cytobase** (approval required)  
Others: (Please indicate below) 
                            to        
                            to        
* Note: all studies planning use of CCN data must be approved by an external process through Program Lead - CardioDIP  
** All studies planning use of Cancer Care Ontario  databases (ie, OCR, OBSP, Cytobase) must be logged and submitted to Cancer Care Ontario by Chief 
Privacy Officer (contact for details) and approved by additional process. 
† Written application for use of Stroke Data is required 
Written application / approval required by Program Lead - CardioDIP 
Surveys                                                     Linked 
  OHS*         
  NPHS*      
  CCHS*       
  PCAS       
  OTHER:        
* Restricted to MOHLTC mandated and/or funded projects. 
 
Other Databases                                                                                 Year 
  ARIS                                                   to        
  MIS                                                   to        
  OTR                                                   to        




  Others: (Please indicate below) 




12)  i)   Is probabilistic linkage planned?                                                                    Y   N 
      ii)   Please list any personal health information/data that will be collected and / or used in this 
study, which potentially, alone or in combination, could be associated with increased risk to 
privacy (identification of the individual).   
 
  Birth date            Postal Code            Other (list below) 
 
      
 
C. DATA SECURITY/PRIVACY IMPACT 
 
A.  Internal Projects: 
1)     Complies with all ICES policies / procedures   Y  










B.  External Projects (e.g. Chart abstraction, EHM/EMR, primary data collection) have special privacy and 
security data concerns.  
ICES Staff Research Coordinator and/or Analyst should be designated for these projects.                                                                       
 
1)     Complies with all ICES policies / procedures                         
  Y 
         Describe perceived need for modification:  




2)      MRNs sent to hospitals in password-protected Excel files  
(see SOP DM005 ) 





3)     For primary data collection projects using laptops/USB key/mobile devices:  
• Encryption software in place.    Y 
• 2 levels of unique passwords must comply with ICES password policy.   Y 
• Anonymization at collection point: collected under unique study number.   Y 
• Data collection tool complies with ICES standards for primary databases on 
laptops. (see Mobile Devices Policy) 
  Y 
  
 
4)     Are complete copies of reports / tests required? 
  Y      N 
        If Yes:  
• Limited numbers of reports may be scanned where abstraction difficult or 
untenable. Consult the Privacy Office. 
  Y 
• Paper reports / tests will be de-identified; assigned a unique number only and 
couriered to ICES. 





5)      Append methods describing encryption methods and protections, if you plan 
to transmit data back to ICES. 
  Y 
 
 
D. PUBLIC BENEFIT 
(Legislation requires completion of this section) 
 
1)      What is the public benefit of this Data use: (eg. Research that contributes to the effectiveness, 
quality, equity and efficiency of health care in Ontario) that are expected / anticipated from the 
project? Identify any potential impact. 
 
The purpose of this project is to determine the incidence, treatment trends and 5 year survival 
of patients with laryngeal cancer treated in the province of Ontario from 1991-2010. Laryngeal 
cancer is divided into three subsites: subglottic; supraglottic and glottic. Several randomized 
controlled trials performed more than twenty years ago have demonstrated improved 5-year 
survival and improved laryngectomy-free survival when chemotherapy is added to radiotherapy. 
The method of delivering radiothrapy has changed since these landmark studies (specifically, the 
current method is IMRT versus conventional radiation). Additionally, the last 10 years has seen a 
rise in minimally invasive surgery for laryngeal cancer. The proposed project will determine 
whether changes in treatment for laryngeal cancer has influenced the 2, 3 and 5 year survival 
and laryngectomy-free survival from 1991-2010. This project has the potential to change the 










E. ESTIMATION OF HARM 
(Legislation requires completion of this section) 
 
Note: Cell sizes less than or equal to 5 cannot be reported without prior written approval from the 
President and CEO of ICES. 
 
1)      Please describe the level at which the results will be reported (e.g. level of individuals, institution or 
region – smallest units) 
The results will be reported at the aggregate level and results less than 5 will be supressed and 





2) Describe any reasonably foreseeable harms that may arise from the use of the data. Are there any 
ways this study might identify, stigmatize, or otherwise harm patients, practitioners or 
institution(s)? How will these reasonably foreseeable harms be addressed? 





(Legislation requires completion of this section) 
 
1)      Is it possible to do this research without using personal health information?  





2)      Were any alternative methods considered / rejected as less privacy-invasive for 
achieving the desired objectives? If so, please describe briefly (this provides a 
means of assessing any real / potential privacy-adverse impact which may be 
challenged by external sources). 
 
  Y      N 
 
Randomized controlled trials were not considered feasible due to the high cost and long-term 






G. TIMEFRAME, DATA RETENTION/DESTRUCTION  
 
1)   What is the proposed time frame of the project: 
• Anticipated start-up date:  01/05/2013 (dd/mm/yyyy) 
• Anticipated completion date: 30/05/2014 (dd/mm/yyyy) 
 
2)   Retention and disposal policies. 
Stipulate retention prior to dataset destruction period. 
Notification to PI to be sent on: Jan-13 (mm/yy) 
• Document shredding.   Y 
• Destruction of electronic media (magnetic and optical disks, cartridges, CDs).   Y 
• Dataset Destruction date: 30/05/2018 (dd/mm/yy): 
 
H.  FINANCIAL INFORMATION 
 





 ICES – Core Budget * 
* Do not use unless expenditures have been pre-approved and included in the ICES core budget. 
• Ministry Workplan (MOHLTC)*   Y 
• ICES Funded (non-MOHLTC/non-grant)*   Y 
 
 
 Externally Funded 
• MOHLTC Program Funded (Special Projects) 
• CCO 
  Y  
  Y 
• Peer Reviewed Grant (Specify Source)          Y 
• External Contract 
• MOHLTC Third Party Funded (MOHLTC funds held at another institution.) 
• Other funding source (Specify Source) ICES@Western Faculty Scholars 
Program 
  Y  
  Y 
  Y 
 
 
2)     PAW: Have you completed and submitted a Project Activation Worksheet?   Y     
 





I. ETHICS APPROVAL STATUS 
• Ethics approval sought by President and CEO and Chief Privacy Officer 
(anonymized data studies with administrative data) 
  Y 
• Chart abstraction study – ethics approval obtained (append copies of REB 
approval) 
  Y 
• Clinical study – ethics approval obtained (append copies of REB approval) (Include 
patient consent form if applicable.) 
  Y 
J. COMPLIANCE WITH CORPORATE RULES FOR ALL STAFF 
 
Is a data-sharing agreement required for this project?              Y  N 
• If yes:  
o Has the Privacy Office and the Program Administrator been 
notified? OR 
o Data sharing agreements have been signed. 
 
 
  Y  N 
  Y  N 
• Confidentiality agreements have been signed by ALL project staff.   Y 
• All project participants have been familiarized with ALL ICES privacy and 
confidentiality policies and procedures. 
  Y 
• Copies of proposal, Privacy Impact Assessment form and Project Activation 
Worksheets have been filed with the Program Administrator.  Electronic copies of 
each of these have been sent to the ICES Privacy Office. 
  Y 
• If external Ethics approval has been sought, append copy to documents   Y 
• Cell sizes less than or equal to 5 cannot be reported (any exceptions must be 
approved in writing by ICES President and CEO). 
  Y 
• Your interest in the disclosure of the data for your research purpose will not result 
in actual, perceived or potential conflict of interest with your other duties as 
researcher. 
  Y 
• You have received and agree with ICES Media Relations Policy   Y 
• You have read and agree with the ICES Conflict of Interest Policy   Y  
 
K. SOP’S AND POLICIES 
 
• You and your project team have reviewed all current Policies and SOP’s applicable 
to this project  
  Y    N 
 




• ICES Intranet – under “Policies and Forms” 
• ICES Research Practice site 
 
• For access to the documents, please contact your Program Administrator.  







________________________________       ___________________________________ 





________________________________       ___________________________________ 





________________________________       ___________________________________ 





___________________________________        ___________________________________ 





___________________________________        ___________________________________ 














________________________________  ___________________________________ 
Signature     Date (dd/mm/yy) 
 
      on behalf of  
        CCO 
         Cancer Research Program 
   
*Reference:  
 
For more information, please refer to the Personal Health Information Protection Act (PHIPA) which is found at:  
http://www.e-laws.gov.on.ca/html/statutes/english/elaws_statutes_04p03_e.htm 
 
The Regulation to the Act (Reg. 329/04) can be found at: 
http://www.e-laws.gov.on.ca/html/regs/english/elaws_regs_040329_e.htm 
 





APPENDIX F Curriculum vitae  
Schulich School of Medicine & Dentistry 
Professional Curriculum Vitae 
MAY 24, 2021 
 
DR. S. DANIELLE MACNEIL 
MD, MSc, FRCSC 
 
 
Assistant Professor - Department of Otolaryngology - Head & 
Neck Surgery 





Name  S. Danielle MacNeil 
 
Date of Birth  1978 Apr 12 
 








EDUCATION AND QUALIFICATIONS 
 
Degrees and Diplomas 
2013 - present Master of Science, Western University, Epidemiology and Biostatistics, Master’s 
Thesis, EPIDEMIOLOGY, London, Ontario, Canada 
2006 Bachelor of Science, Dalhousie University, Medicine, Bachelor’s - Equivalent, Halifax, 
Nova Scotia, Canada 
2006 Doctor of Medicine, Dalhousie University, Medicine, Doctor (Medical), Halifax, Nova 
Scotia, Canada 
2002 Master of Science, Dalhousie University, Pathology, Master’s Thesis, Halifax, Nova 
Scotia, Canada 
1999 Bachelor of Science, University of Guelph, Biological Science, College of, Bachelor’s - 
Honours, Guelph, Ontario, Canada 
 
Research Training 
2013 - 2015 Western University, ICES Faculty Scholars, Population database subject, Supervisor: 
Amit Garg, Ontario, Canada 
 
Specialized Training 
2018 Course Participant, Department of Oncology, Meditation and Leadership Retreat, 
Ontario, Canada 
2012 University of Alberta, Advanced Head and Neck Oncology and Microvascular 
Reconstruction Fellow, Edmonton, Alberta, Canada 
2011 Royal College of Physicians and Surgeons of Canada, Fellow, Canada 
2011 University of British Columbia, Otolaryngology Residency, British Columbia, Canada 
 
Qualifications, Certifications and Licenses 
2019 Ontario Core Indigenous Cultural Safety Health Course Certificate, Indigenous 
Cultural Safety Ontario, Certificate, Ontario, Canada 
2019 CIHR Institute of Gender and Health Core 
Competency Module for Sex and Gender in Biomedical Research. CIHR, License, 
Ontario, Canada 
2019 CIHR Institute of Gender and Health Core 
Competency Module for Sex and Gender in Primary Data Collection with 







2016 - 2022 Assistant Professor, Otolaryngology - Head & Neck Surgery, Schulich School of 
Medicine & Dentistry, The University of Western Ontario 
2013 - 2015 Lecturer, Otolaryngology - Head & Neck Surgery, Schulich School of Medicine & 
Dentistry, The University of Western Ontario 
2016 - 2022 Assistant Professor, Department of Oncology, Schulich School of Medicine & 
Dentistry, The University of Western Ontario 
2013 - 2015 Lecturer, Department of Oncology, Schulich School of Medicine & Dentistry, The 
University of Western Ontario 
 
Clinical Appointments 





POSITIONS HELD & LEADERSHIP EXPERIENCE 
 
Academic Positions 
2019 - present Associate Scientist, Lawson Health Research Institute, London, Ontario, Canada 
 
Clinical Positions 
2019 - present CCO Ontario Head and Neck Cancer Advisory Committee 
2019 - present LRCP Head and Neck Cancer Survivorship Committee Chair 
2019 - present Chair Head and Neck Disease Site Team, London Regional Cancer Program, London, 
Ontario, Canada 








2019 AAO Cochrane Scholars Award, Recipient of 2019 AAO Cochrane Scholars Award to 
receive funding to attend the Cochrane Colloquium in Santiago, Chile in October 
2019. American Academy of Otolaryngology, $3,300, Type: Research award, 
International 
2012 Top Paper, Canadian Society of Otolaryngology Annual Meeting, Toronto, Ontario, 
Canada 
2011 Lavell H. Leeson, Award for resident achieving highest academic standing, Division of 
Otolaryngology, University of British Columbia, Type: Distinction, British Columbia, 
Canada 
2011 A.W.D. Bill Knox, Award for outstanding postgraduate surgical study, Department of 
Surgery, University of British Columbia, Type: Distinction, British Columbia, Canada 
2010 Research Grant Award, Branch for International Surgery Research Grant Award, 
University of British Columbia, British Columbia, Canada 
2009 Research Award, Division of Otolaryngology Research Award, University of British 
Columbia, British Columbia, Canada 
2004 Research Scholarship, Dalhousie Medical Research Foundation B.Sc. (Medicine), 
Dalhousie University, Halifax, Nova Scotia, Canada 
2003 Research Scholarship, Dalhousie Medical Research Foundation B.Sc. (Medicine), 
Dalhousie University, Halifax, Nova Scotia, Canada 
2003 Research Grant, Category A Research Grant, IWK Health Centre, Canada 
2002 John G. Quinlan, Memorial Bursary, Canada 
2001 Research Placement Grant, Aquanet Educational Research Placement Grant, Canada 
2000 Graduate Scholarship, Dalhousie University Graduate Scholarship, Dalhousie 
University, Halifax, Nova Scotia, Canada 
1995 Entrance Scholarship, York University Entrance Scholarship, Toronto, Ontario, Canada 
1995 Science Scholarship, York University Science Scholarship, Toronto, Ontario, Canada 
1995 Entrance Scholarship, Rotary Club University Entrance Scholarship, Rotary Club, 
Canada 








2018 Department of Otolaryngology-Head and Neck Surgery Faculty Teaching Award, 
Level: Postgraduate, Scope: Department, Western University, Schulich School of 




SERVICE AND ADMINISTRATION 
 
Professional Affiliations and Activities 
Professional Associations 
2007 - present American Academy of Otolaryngology-Head and Neck Surgery 
2006 - present Canadian Society of Otolaryngology-Head and Neck Surgery 
2003 - present Canadian Medical Association 
 
2018 - present Chair, Awards Committee CSO 
2018 - present Chair, CSO Women in Otolaryngology Committee 
 
2019 - 2021 Consultant, AAO-HNS/F- WIO Leadership Development and Mentorship 
 
2018 - present Member, American Head and Neck Society- Survivorship Committee 
2018 - present Member, PGE Committee 
2018 - present Member, Competency Committee 
2018 - present Member, American Head and Neck Society- Women in Head and Neck Surgery 
2018 - 2020 Member, AMOSO Opportunities Fund Committee 
2018 - 2020 Member, Selection Committee Vice-Dean of Dentistry 
2018 - 2020 Member, SRTP Committee 
2018 - present Member, American Head & Neck Society Women in Otolaryngology 
2018 - present Member, American Head & Neck Society 
2018 - present Member, IFOS Head and Neck Oncology Scientific Program Committee 
 
Peer Review Activities 
Journal Reviewer 
2020 - present Manuscript Reviews, BMJ Open 
2017 - present Manuscript Reviews, PLOS ONE 
2017 - present Manuscript Reviews, Manuscript reviewer CMAJ 
2016 - present Manuscript Reviews, Manuscript reviewer JAMA- Otolaryngology 
2015 - present Manuscript Reviews, Manuscript reviewer Clinical Case Reports 
2015 - present Manuscript Reviews, Manuscript reviewer Medicine Journal 
2015 - present Manuscript Reviews, Manuscript reviewer current oncology 









2018 - present Member, Survivorship/Supportive Care/Rehabilitation Service, Total Number of 
Meetings: 4, Total Hours: 4 
2018 - present Member, Women in Head and Neck Surgery Service, Total Number of Meetings: 4, 
Total Hours: 4 
American Academy of Otolaryngology-Head and Neck Surgery 
2019 - present Member, WIO Leadership Development and Mentorship, Total Number of Meetings: 
2, Total Hours: 2 
American Society of Head and Neck Surgery 
2020 Member, AHNS Women in HNS Margaret F. Butler Award Selection Committee, Total 
Number of Meetings: 1, Total Hours: 2 
Main Activities: Review and selection of award recipient 
Association of Women Surgeons 
2018 - present Member, Association of Women Surgeons, Total Number of Meetings: 3, Total 
Hours: 3 
International Federation of ORL Societies 
2020 - 2021 Member, IFOS Vancouver 2021 Physician Health, Wellness and Diversity Committee, 
Total Number of Meetings: 2, Total Hours: 3 
2019 - 2021 Member, IFOS 2021 Head and Neck Oncology Scientific Program Committee, Total 
Number of Meetings: 4, Total Hours: 8 




Canadian Society of Otolaryngology 
2018 - 2021 Chair, CSO Poloquin Awards, Total Number of Meetings: 8, Total Hours: 40 




2016 - present Member, CSO Collaborative Research Committee Core Group, Total Number of 
Meetings: 33, Total Hours: 33 
2016 - present Member, CSO Collaborative Research Committee Head and Neck Group, Total 
Number of Meetings: 33, Total Hours: 33 
2015 - 2016 Member, Poloquin Resident Research Award Committee, Total Number of Meetings: 
2, Total Hours: 10 
Main Activities: Review and judge resident abstract and manuscripts. Panel member 





2018 - present Member, AMOSO Opportunities Fund Sub-Committee, Total Number of Meetings: 4, 
Total Hours: 16 
Western University 
2018 - 2019 Member, Selection Committee Vice-Dean of Dentistry, Total Number of Meetings: 2, 
Total Hours: 10 
Main Activities: Selection committee member including interviews of vice-dean of 
dentistry 
Contribution: 20 
Western University Department of Otolaryngology 
2016 - present Member, Postgraduate Committee, Total Number of Meetings: 28, Total Hours: 80 
Main Activities: Attend 6 meetings per year. 
2016 - 2019 Member, Summer Research Training Program, Total Number of Meetings: 4, Total 
Hours: 8 




2004 Council Member, Research Opportunities in Medical Training Committee 
University of British Columbia 




2009 Council Member, Residency Training Committee, Division of Otolaryngology 
University of Guelph 
1998 Council Member, Human Rights Coordinator Hiring Committee 
1998 Council Member, Student Health and Dental Plan Implementation Committee 
1998 Council Member, University Centre Board of Directors 
1998 Council Member, University Senate 













2018 Sep - 2020 Sep 
 
Role: Principal Applicant 
Title: Geographic disparities in survival amongst head 
and neck cancer patients 
 
Funding Source: Canadian Institutes of Health 
Research (CIHR) 
Principal Investigator: Danielle MacNeil 
Grant Total: $370,000 
 
Industry Grant: N 
 
2018 Sep - 2020 Sep 
 
Role: Co-Applicant 
Title: A Phase II Randomized Trial of Treatment De-
Escalation for HPV-Associated Oropharyngeal 
Squamous Cell Carcinoma: 
Radiotherapy vs. Trans-Oral Surgery (ORATOR II) 
 
Funding Source: CIHR 
Principal Investigator: Anthony Nichols 
Grant Total: $1,140,000 
 
Industry Grant: N 
 
2018 Mar - 2020 Mar 
 
Role: Principal Applicant 
Title: Survivorship after Head and Neck Cancer 
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Co-Investigators: David Palma 
 
Funding Source: CCSRI 
Principal Investigator: Danielle  MacNeil 
Grant Total: $194,400 
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Role: Principal Applicant 
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Funding Source: Cornell University Principal Investigator: Danielle MacNeil 
Grant Total: $1,000 
 
Industry Grant: N 
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Role: Principal Investigator 
Title: Head and Neck Survival Outcomes: Impact of 
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Funding Source: Department of Otolaryngology-
Head and Neck Surgery Research Fund Pilot Study 
Principal Investigator: Danielle MacNeil 
Grant Total: $15,000 
 
Industry Grant: N 
 
2018 Jan - 2019 Jan 
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Title: Geographic Disparities Head and Neck Cancer 
 
Funding Source: London Regional Cancer Program 
Catalyst Grant Principal Investigator: Danielle MacNeil 
Grant Total: $29,468 
 
Industry Grant: N 
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Funding Source: St. Joseph’s Hospital Foundation 
Principal Investigator: Brian Rotenberg 
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Industry Grant: N 
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Dave Nagpal 
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16. MacNeil SD, Romney MG, Westerberg BW. Towards the development of evidence-based guidelines 
for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA) otitis. University of British 
Columbia Department of Surgery Chung Research Day. 2009 Nov, Presenter 
17. MacNeil SD, Moxham JP. Systematic review of floor of mouth dermoid cysts. COSM Western 
Section Meeting. Las Vegas NV. 2009 Jan, Presenter 
18. D. MacNeil, A. Mallinson, J. Galo, N. Longridge, Vestibular Evoked Myogenic Potential (VEMP) 
Abnormalities in Patients with Visual Vestibular is Match, 2009, British Columbia, Canada, Presenter 
19. S. Danielle MacNeil, The Reliability of the Reflux Finding Score Among General Otolaryngologists, 
2008 Jun 1, Canadian Society of Otolaryngology, Alberta, Canada, Presenter 
20. D. MacNeil, The Reliability of the Reflux Finding Score Among General Otolaryngologists, 2008, 
British Columbia, Canada, Presenter 
21. MacNeil SD, Fernandez CV. Informing Research Participants of Research Results: Analysis of 
Canadian University-based Research Ethics Board Policies. Ethics of Bioethics Conference. 




22. MacNeil SD, Pohajdak B, Wright JR. The Development of Tilapia (Oreochromis niloticus) Chimeras 
and Short-term Culture of Undifferentiated Embryo Cells. Department of Pathology Research 
Seminar, Dalhousie University. Halifax, NS. 2002 Apr, Presenter 
 
Posters Presented 
1. Lina Samargandy, Sarah Nixey, Stan Van Uum, Danielle MacNeil, Irina Rachinsky, Long term 
outcomes of distant metastasis from differentiated thyroid cancer and prognostic factors associated 
with disease-specific survival, 2019 Oct 30, Chicago, Illinois, United States, Co-Author 
2. Lina Samargandy, Sarah Nixey, Stan Van Uum, Danielle MacNeil, Irina Rachinsky, Prognostic factors 
of disease progression in patients with metastatic differentiated thyroid carcinoma, 2019 Oct 30, 
Chicago, Illinois, United States, Supervisor 
3. Hamilton S, Weir M, Nichols A, Fung K, Yoo J, Zeman-Pocrnich C, MacNeil D, A retrospective study 
of the natural history of thyroid nodules with indeterminate cytopathology, 2019 Oct 30, Chicago, 
Illinois, United States, Supervisor 
4. Rucci K, Means J, Sun R, Rizzo G, Pinto N, Yoo J, Fung K, MacNeil D, Barrett JW, Boutros P, Ailles L, 
Nichols A, A Controlled Trial of HNSCC Patient-derived Xenografts Reveals Broad Efficacy of PI3K-
alpha Inhibition in Control Tumor Growth, 2019 Jun 3, Co-Author 
5. Mundi N, Prokopec S, Ghasemi F, Warner A, MacNeil D, Howlett C, Boutros P, Nichols A, Genomic 
and Human Papillomavirus Profiling of an Oral Cancer Cohort Identifies TP53 as a Predictor of 
Overall Survival, 2019 Jun 3, Co-Author 
6. Kim L, Sahovaler A, Fung K, Nichols A, Yoo J, MacNeil D, The Prevalence of HPV in Non-
Oropharyngeal Head and Neck Squamous Cell Carcinomas and its Implications: A Systematic 
Review, 2019 Jun 3, Canadian Society of Otolaryngology, Supervisor 
7. Dwyer C, MacNeil D, Nichols A, Yoo J, Inculet R, Qiabi M, Malthaner R, Fung K, Idiopathic Subglottic 
Stenosis: An Institutional Review of Surgical Treatment Outcomes, 2019 Jun 3, Canadian Society of 
Otolaryngology, Co-Author 
8. Risk factors and Outcomes of metastatic cutaneous Squamous Cell Carcinoma in the Head and Neck 
Region: Systematic Review and Meta-analysis, 2018 Jun 16, 72nd CSOHNS Annual Meeting, Quebec, 
Canada, Supervisor 
9. Dr. Laura Kim, Radiologic Assessment of the Lateral Scapula and Scapular Tip for Dental Implant 
Suitability in Patients Undergoing Mandibular Reconstruction, 2018 Jun 16, 72nd CSOHNS Annual 
Meeting, Quebec, Canada, Co-Author 
10. Dr. Axel Sahovaler, Finding Unknown Primaries: A Canadian Head and Neck Surgery Referral Center 
Experience, 2018 Jun 16, 72nd CSOHNS Annual Meeting, Quebec, Canada, Co-Author 
11. Dr. Axel Sahovaler, Decreasing Morbidity of the FAMM Flap: Comparing Traditional and Modified 
Harvesting Techniques, 2018 Jun 16, 72nd CSOHNS Annual Meeting, Quebec, Canada, Co-Author 
12. F. Ghasemi, High-throughput Testing in Head and Neck Squamous Cell Carcinoma Identifies Agents 
with Preferential Activity in HPV-positive and Negative Cell Lines, 2018 Jun 16, 72nd CSOHNS Annual 




13. F. Ghasemi, Mutational Analysis of Head and Neck Squamous Cell Carcinoma Stratified by Smoking 
Status Identified NSD1 Mutations as a Biomarker of Survival, 2018 Jun 16, 72nd CSOHNS Annual 
Meeting, Quebec, Canada, Co-Author 
14. Dr. A. Nichols, Genomic and Human Papillomavirus Profiling of a Canadian Oral Cancer Cohort, 2018 
Jun 16, 72nd CSOHNS Annual Meeting, Quebec, Canada, Co-Author 
15. Dr. H. Ernst, RAPSTOR: Development of a Rapid Standardized OR for Thyroid Surgery, 2018 Jun 16, 
72nd CSOHNS Annual Meeting, Quebec, Canada, Co-Author 
16. Dr. A. Sahovaler, Novel Minimally Invasive Pharyngeal Surgery (MIPS) Hemorrhage Model 
Implemented in a Nationwide Otolaryngology Emergencies Bootcamp: Importance and Outcomes, 
2018 Jun 16, 72nd CSOHNS Annual Meeting, Quebec, Canada, Co-Author 
17. F. Ghasemi, Repurposing Albendazole: New Potential as a Chemotherapeutic Agent with 
Preferential Activity Against HPV-negative Head and Neck Squamous Cell Cancer, 2017 Jun 11, 71st 
CSOHNS Annual Meeting, Saskatchewan, Canada, Co-Author 
18. S. Kassirian, Delay in Diagnosis of Oral Cavity Carcinoma: The Impact of Referral Source, 2017 Jun 
11, 71st CSOHNS Annual Meeting, Saskatchewan, Canada, Supervisor 
19. Dr. Benjamin van der Woerd, Sialocutaneous Fistula to the External Auditory Canal Repaired with 
Superficial Parotidectomy and Temporoparietal Flap: A Case Report, 2017 Jun 11, 71st CSOHNS 
Annual Meeting, Saskatchewan, Canada, Supervisor 
20. J. Athayde, Thyroid Lobectomy versus Total Thyroidectomy in the Treatment of Well-Differentiated 
Thyroid Cancer 1-4cm in Size: A Systematic Review and Meta-Analysis, 2017 Jun 11, 71st CSOHNS 
Annual Meeting, Saskatchewan, Canada, Supervisor 
21. C. Best, D. MacNeil, Echocardiogram changes following parathyroidectomy in patients iwth primary 
hyperparathyroidism: A systematic review and meta-analysis, 2016 Jul 17, International Conference 
on Head and Neck Cancer, Seattle, Washington, United States, Co-Author 
22. H. Low, K. Patel, A. Partridge, D. MacNeil, A. Nichols, J. Yoo, K. Fung, Shoulder Function after 
Scapular Free Flap, 2016 Jul 17, International Conference on Head and Neck Cancer, Seattle, 
Washington, United States, Co-Author 
23. K. Patel, H. Low, A. Partridge, D. MacNeil, A. Nichols, J. Yoo, K. Fung, Shoulder Function After 
Scapula Free Flap, 2016 Jun 12, 70th CSOHNS Annual Meeting, Prince Edward Island, Canada, Co-
Author 
24. A. Nichol, M. Black, K. Ruicci, N. Pinto, J. Barrett, J. Yoo,  K. Fung, D. MacNeil, Syk as a Novel 
Therapeutic Target in HNSCC, 2016 Jun 12, 70th CSOHNS Annual Meeting, Prince Edward Island, 
Canada, Co-Author 
25. D. MacNeil, K. Ioanidis, Case Report: An Atypical Lipomatous Tumour Mimicking a Giant 
Fibrovascular Polyp of the Hypopharynx, 2016 Jun 12, 70th CSOHNS Annual Meeting, Prince Edward 
Island, Canada, Supervisor 
26. A. Nichols, M. Black, J. Barrett, J. Yoo, K. Fung, D. MacNeil, E. Qinquist, D. Palma, Xenograft Directed 
Care for Recurrent and Metastatic Head and Neck Cancer: Description of a Novel Clinical Trial, 2016 




27. K. Patel, H. Low, A. Partridge, D. MacNeil, A. Nichols, J. Yoo, K. Fung, The Incidental Thyroid lesion in 
Parathyroid Disease Management, 2016 Jun 12, CSO 2016, Prince Edward Island, Canada, Co-Author 
28. C. Best, D. MacNeil, Echocardiogram Changes Following Parathyroidectomy in Patients with Primary 
Hyperparathyroidism: A Systematic Review and Meta-analysis, 2016 Jun 12, 70th CSOHNS Annual 
Meeting, Prince Edward Island, Canada, Supervisor 
29. C. Best, S. Dhaliwal, S. Tam, H. Low, K. Fung, B. Hughes, D. MacNeil, Spontaneous, Slowly Expanding 
Intrathyroidal Hematoma Causing Airway Obstruction: A Case Report, 2016 Jun 12, CSO 2016, 
Prince Edward Island, Canada, Supervisor 
30. Zhang TW, Low TH, Yeh D, Araslanova R, Hammond JA, Palma DA, Read N, Fung K, MacNeil SD, 
Nichols AC, Yoo J, Venkatesan V, Outcomes of Stage II Glottic Cancer in a Single Institution: 
Conventional vs. Intensity Modulated Radiotherapy, 2015 Sep 7, Canadian Radiation Oncology 
(CARO) Conference, Ontario, Canada, Co-Author 
31. Zhang TW, Low TH, Yeh D, Araslanova R, Hammond JA, Palma DA, Read N, Fung K, MacNeil SD, 
Nichols AC, Yoo J, Venkatesan V, Outcomes in T1 Glottic Cancer Treated with 
Radiotherapy: A Single Institution Experience, 2015 Sep 7, Canadian Radiation Oncology (CARO) 
Conference, Ontario, Canada, Co-Author 
32. S. Tam, J. Theurer, A. Grewal, S. Hawkins, D. MacNeil, A. Nichols, J. Yoo, K. Fung, Dysphagia 
Following Salvage Neck Dissection: A Prospective Cohort Study, 2015 Jun 8, 69th CSOHNS Annual 
Meeting, Winnipeg, Manitoba, Canada, Co-Author 
33. P. Doyle, K. Fung, J. Theurer, D. MacNeil, J. Yoo, Exploring the Functional Influence of Flap 
Reconstruction on Tracheosophageal Voice Production, 2015 Jun 7, 69th CSOHNS Annual Meeting, 
Winnipeg, Manitoba, Canada, Co-Author 
34. T. H. Low, A. Partridge, P. Doyle, J. Theurer, K. Fung, A. Nichols, D. MacNeil, J. Yoo, Patient and 
Observer Assessment of Donor Site Scars for Head and Neck Reconstruction- Implications for Donor 
Site Selection, 2015 Jun 7, 69th CSOHNS Annual Meeting, Winnipeg, Manitoba, Canada, Co-Author 
35. K. Patel, D. MacNeil, K. Liu, J. Shariff, J. Yoo, A. Nichols, K. Fung, A. Garg, Survival of Patients with 
Subglottic Squamous Cell Carcinoma, 2015 Jun 7, 69th CSOHNS Annual Meeting, Winnipeg, 
Manitoba, Canada, Supervisor 
36. S. Tam, T. H. Low, J. Theurer, A. Partridge, K. Fung, A. Nichols, D. MacNeil, J. Yoo, The Infraclavicular 
Pedicled Adipofascial Flap for Recontouring the Neck following Neck Dissection, 2015 Jun 7, 69th 
CSOHNS Annual Meeting, Winnipeg, Manitoba, Canada, Co-Author 
37. S. Danielle MacNeil, Samantha Tam, Kyan Liu,  Amit X Garg, Amardeep Thind, Eric Winquist, John 
Yoo, Anthony Nichols, Kevin Fung, Stephen Hall, Salimah Z Shariff, Incidence of perioperative 
ischemic stroke after neck dissection, 2015, Boston, Massachusetts, United States, Poster Presenter 
38. Murphy R, O’Connell DA, Seikaly H, Harris J, MacNeil SD. Locoregional Recurrence in Free Flap 
Surgery for Advanced Stage Head and Neck Cancer. International Conference on Head and Neck 




39. MacNeil SD, Yu J, Grosvenor A, Osswald M, Dobrovolsky W, Ansari K, O’Connell DA, Wolfaardt J, 
Seikaly H. Maxillary Reconstruction with Digital Pre-Planning and Prefabrication of Fibular Free 
Flaps. International Conference on Head and Neck Cancer. Toronto, ON . 2012 Jul, Presenter 
40. MacNeil SD, Osswald M, Wolfaardt J, Ansari K, O’Connell DA, Grosvenor A, Harris J, Seikaly H. Digital 
Planning Improves the Accuracy of Mandibular and Maxillary Reconstruction. International 
Conference on Head and Neck Cancer. Toronto, ON. 2012 Jul, Presenter 
41. Towles R, MacNeil SD, Berean K, Anderson D, Garnis C. The Molecular Characterization of 
Anaplastic Thyroid Cancer. Department of Surgery Chung Research Day. Vancouver, BC. 2010 Oct, 
Presenter 
42. MacNeil SD, Moxham JP, Kozak FK. Nasopharyngeal foreign bodies may mimic lower airway 
locations. ABEA: COSM. May 2008. Orlando, FA. 2010, Presenter 
43. MacNeil SD, Moxham JP, Kozak FK. Nasopharyngeal foreign bodies may mimic lower airway 
locations. 2010, COSM: ABEA, Orlando, Florida, United States, Presenter 
44. MacNeil SD, Westerberg BW, Romney MG. Topical antibiotics for the treatment of Methicillin-
resistant staphylococcus aureus otorrhea: a systematic review of the literature. Canadian Society of 
Otolaryngology Annual Meeting. Montreal, QC. 2007 May, Presenter 
45. Kent J, MacNeil SD, Javer A. Eosinophilic Angiocentric Fibrosis (EAF) causing bilateral complete nasal 
obstruction: Case Report and Review of the Literature. Canadian Society of Otolaryngology Annual 
Meeting. Montreal, QC. 2007 May, Presenter 
46. MacNeil SD, Westerberg BW, Romney MG. Topical antibiotics for the treatment of Methicillin-
resistant staphylococcus aureus otorrhea: a systematic review of the literature. 2007, Canadian 
Society of Otolaryngology Annual Meeting 2007, Montreal, Quebec, Canada, Presenter 
47. MacNeil SD, Wright E. Multi-Port Technique for Drainage of Unilateral Frontal Sinusitis. Canadian 
Society of Otolaryngology Annual Meeting. Kelowna, BC. 2006 May, Presenter 
48. MacNeil SD, Fernandez CV. Informing Research Participants of Research Results: An Analysis of the 
Attitudes of Canadian University-based Research Ethics Board Chairs. IWK Health Centre 
Department of Pediatrics Research Day. Halifax, NS. 2005 Apr, Presenter 
49. MacNeil SD, Kodish E, Fernandez CV. Informing Research Participants of Research Results: An 
Analysis of Pediatric Informed Consent Conference in Randomized Controlled Trials. IWK Health 
Centre Department of Pediatrics Research Day. Halifax, NS. 2004 May, Presenter 
50. MacNeil SD, Kodish E, Fernandez CV. Informing Research Participants of Research Results: An 
Analysis of Pediatric Informed Consent Conference in Randomized Controlled Trials. Faculty of 
Medicine Research Day.  Halifax, NS. 2003 Dec, Presenter 
51. MacNeil SD, Lu X, Pohajdak B, Wright JR. The Development of a Tilapia (Oreochromis niloticus) 








1. Co-Author, Functional Outcomes Following Pharyngoesophageal Reconstruction with the Gastric 
Pull Up, Canadian Society of Otolaryngology, Presenters: Butskiy O, Rahmanian R, MacNeil D, 





1. Organizer, Survivorship, London Regional Cancer Program Multidisciplinary Retreat, 2019 Mar 5, 
London, Ontario, Canada, Scientific Presentation 
2. Presenter, Survivorship, McGill University, 2018 Nov 12, Montreal, Quebec, Canada, Scientific 
Presentation 
National 
1. Co-Author, Gender Disparity in Head and Neck Cancer Driver Genes: An Analysis of the TCGA 
Dataset, Canadian Society of Otolaryngology, Presenters: Mundi N, Ghasemi F, MacNeil D, Fung K, 
Yoo J, Nichols A, 2019 Jun 4, Scientific Presentation 
2. Presenter, ORATOR 3, London Regional Cancer Program Multidisciplinary Retreat, 2019 Jan 12, 
Toronto, Ontario, Canada, Scientific Presentation 
3. Supervisor, Prevalence of Obstructive Sleep Apnea in Head and Neck Patients: A Systematic Review, 
72nd CSOHNS Annual Meeting, Presenters: Dr. Krupal Patel, 2018 Jun 19, Quebec, Canada, Scientific 
Presentation 
4. Supervisor, Functional Outcomes in Early (T1/T2) Supraglottic Cancer: A Systematic Review, 72nd 
CSOHNS Annual Meeting, Presenters: Dr. Benjamin van der Woerd, 2018 Jun 18, Quebec, Canada, 
Scientific Presentation 
5. Supervisor, Diagnostic Delay in Head and Neck Cancer Patients, 72nd CSOHNS Annual Meeting, 
Presenters: Dr. Shannan Hamel, 2018 Jun 18, Quebec, Canada, Scientific Presentation 
6. Supervisor, Safety of Outpatient Parathyroidectomy for Primary Hyperparathyroidism in a Cohort of 
Unilateral Neck Explorations, 72nd CSOHNS Annual Meeting, Presenters: Dr. Chris Dwyer, 2018 Jun 




7. Supervisor, Total Thyroidectomy versus Thyroid lobectomy for the treatment of low risk well-
differentiated thyroid cancer 1-4 cm in size: a systematic review, 72nd CSOHNS Annual Meeting, 
Presenters: Dr. Axel Sahovaler, 2018 Jun 17, Quebec, Canada, Scientific Presentation 
8. Supervisor, Inclusion of Clinical Features in the Diagnosis of Warthin’s Tumor, 72nd CSOHNS Annual 
Meeting, Presenters: Dr. Thomas So, 2018 Jun 16, Quebec, Canada, Scientific Presentation 
9. Co-Author, The Initial Transoral Robotic Surgery Experience in a Canadian Series, 71st CSOHNS 
Annual Meeting, Presenters: Dr. David Yeh, 2017 Jun 12, Saskatchewan, Canada, Scientific 
Presentation 
10. Co-Author, Shouldering the Load of Mandible Reconstruction: 74 Cases of Oromandibuar 
Reconstruction with the Scapula Tip Free Flap, 71st CSOHNS Annual Meeting, Presenters: Dr. David 
Yeh, 2017 Jun 12, Saskatchewan, Canada, Scientific Presentation 
11. Co-Author, The practicality of 3D Printing for Mandibular Reconstruction, International Conference 
on Head and Neck Cancer, Presenters: J. Prasad, A. Partridge, D. Yeh, K. Fung, A. Nichols, D. 
MacNeil, J. Yoo, 2016 Jul 19, Seattle, Washington, United States, Scientific Presentation 
12. Co-Author, Prior Radiotherapy and age strongly predict survival after salvage surgery for recurrent 
oral cavity squamous cell carcinoma- A recursive partitioning analysis, International Conference on 
Head and Neck Cancer, Presenters: S. Tam, R. Araslanova, H. Low, K. Fung, D. MacNeil, D. Palma, A. 
Nichols, 2016 Jul 18, Seattle, Washington, United States, Scientific Presentation 
13. Co-Author, The mutational landscape of analplastic thyroid cancer, International Conference on 
Head and Neck Cancer, Presenters: A. Nichols, S. Lai, S. Prokopec, N. Pinto, M. Chan, W. Faquin, M. 
Black, J. Yoo, C. Howlett, K. Fung, D. Macneil, J. Koropatncik, A. Datti, F. Vizeocoumar, K. Patel, C. 
Garnis, K. Berean, J. Mymryk, J. Rocco, D. Palma, J. Barrett, D. Wheeler, G. Clayman, P. Boutros, 
2016 Jul 18, Seattle, Washington, United States, Scientific Presentation 
14. Presenter, Does Parathyroidectomy Reverse Mortality Risk in Patients with Primary 
Hyperparathyroidism? A Systematic review and Meta-Analysis, International Conference on Head 
and Neck Cancer, Presenters: Danielle MacNeil, Rohin Krishnan, Monali Malvankar-Mehta, John 
Costella, John Yoo, 2016 Jul 17, Seattle, Washington, United States, Scientific Presentation 
15. Co-Author, Treatment of Early Stage Supraglottic Squamous Cell Carcinoma: Meta-Analysis 
Comparing Primary Surgery Versus Primary Radiotherapy, International Conference on Head and 
Neck Cancer, Presenters: K. Patel A. Nichols, K. Fung, J. Yoo, D. MacNeil, 2016 Jul 17, Seattle, 
Washington, United States, Scientific Presentation 
16. Co-Author, Analysis of Clinical variables associated with plate extrusion in Oromandibular 
reconstruction, International Conference on Head and Neck Cancer, Presenters: J. Prasad, A. 
Nichols, K. Fung, D. MacNeil, J. Theurer, D. Lee, D. Yeh, J. Yoo, 2016 Jul 17, Seattle, Washington, 




17. Co-Author, Patient Eligibility for Osseointegrated Implant-Based Rehabilitation Following Bony 
Reconstruction of the Oral Cavity, 70th CSOHNS Annual Meeting, Presenters: J. Theurer, C. Aragon, 
K. Fung, D. MacNeil, A. Nichols, J. Yoo, 2016 Jun 14, Prince Edward Island, Canada, Scientific 
Presentation 
18. Co-Author, The Practicality of 3D Printing for Mandibular Reconstruction, 70th CSOHNS Annual 
Meeting, Presenters: J. Prasad, J. Yoo, K. Fung, D. MacNeil, A. Nichols, H. Low, A. Partridge, 2016 Jun 
14, Prince Edward Island, Canada, Scientific Presentation 
19. Supervisor, Treatment of Early Stage Supraglottic Squamous Cell Carcinoma: Meta-analysis 
Comparing Primary Surgery versus Primary Radiotherapy, 70th CSOHNS Annual Meeting, 
Presenters: K. Patel, A. Nichols, K. Fung, J. Yoo, D. MacNeil, 2016 Jun 13, Prince Edward Island, 
Canada, Scientific Presentation 
20. Co-Author, A Continuing Epidemic of Human Papillomavirus Related Oropharyngeal Cancer in 
Southwestern Ontario, 70th CSOHNS Annual Meeting, Presenters: A. Nichols, S. Dhaliwal, J. Basmaji, 
J. Yoo, K. Fung, D. Macneil, J. Barrett, J. Mymryk, 2016 Jun 12, Prince Edward Island, Canada, 
Scientific Presentation 
21. Co-Author, An Oral Cavity Wait Time Improvement Initiative: Do Wait Times in Surgeyr and Post-
operative Radiation Matter? 70th CSOHNS Annual Meeting, Presenters: A. Nichols,N. Mundi, S. 
Dhaliwal, J. Basmaji, J. Yoo, K. Fung, D. Macneil, D. Palma, 2016 Jun 12, Prince Edward Island, 
Canada, Scientific Presentation 
22. Co-Author, TORS vs. RT: Development of a Decision board for patients with early Oropharyngeal 
Cancer, 70th CSOHNS Annual Meeting, Presenters: G. Scott, A. Louie, D. MacNeil, A. Nichols, D. 
Palma, J. Yoo, K. Fung, 2016 Jun 12, Prince Edward Island, Canada, Scientific Presentation 
23. Co-Author, Detection of Circulating Thyroid Tumor DNA in Patients with Thyroid Nodules, 70th 
CSOHNS Annual Meeting, Presenters: -K. Patel, N. Cormier, J. Barrett, J. Yoo, D. MacNeil, I. 
Radchinsky, W. stecho, A. Nichols, 2016 Jun 12, Prince Edward Island, Canada, Scientific 
Presentation 
24. Co-Author, Highly Effective Agents Identified by High-throughput Screening of Genetically 
Characterized Anaplastic Thyroid Cancer Cell Lines, 70th CSOHNS Annual Meeting, Presenters: N. 
Pinto, M. Black, J. Yoo, D. MacNeil, K. Fung, A. Datti, J. Barrett, A. Nichols, 2016 Jun 12, Prince 
Edward Island, Canada, Scientific Presentation 
25. Co-Author, Patterns of Failure in Laryngeal Cancer-Glottic versus Supraglottic, 69th CSOHNS Annual 
Meeting, Presenters: D. Yeh, H. Low, T. Zhang, V. Venkatesan, K. Fung, D. MacNeil, A. Nichols, J. 
Yoo, 2015 Jun 9, Manitoba, Canada, Scientific Presentation 
26. Co-Author, Highly Effective Agents Identified in Genetically Characterized Anaplastic Thyroid Cancer 
Cell Lines, 69th CSOHNS Annual Meeting, Presenters: N. Pinto, M. Black, J. Yoo, D. MacNeil, K. Fung, 




27. Co-Author, High Throughput Screening for Drug Discovery in Head and Neck Squamous Cell 
Carcinoma, 69th CSOHNS Annual Meeting, Presenters: M. Black, N. Pinto, J. Yoo, D. MacNeil, K. 
Fung, A. Datti, J. Barrett, A. Nichols, 2015 Jun 8, Winnipeg, Manitoba, Canada, Scientific 
Presentation 
28. Co-Author, Frequency of HPV16 Prevalence and PIK3CA Hot Spot Mutations in early-stage Laryngeal 
Squamous Cell Carcinoma, 69th CSOHNS Annual Meeting, Presenters: M. Black, N. Pinto, J. Yoo, D. 
MacNeil, K. Fung, A. Nichols, 2015 Jun 8, Winnipeg, Manitoba, Canada, Scientific Presentation 
29. Co-Author, Targeted Therapeutics: Optimization of a PIK3CA Mutational Analysis Pathway, 69th 
CSOHNS Annual Meeting, Presenters: J. Theurer, E. Qinquist, D. Palma, J. Yoo, D. MacNeil, K. Fung, 
C. Howlett, A. Nichols, 2015 Jun 7, Winnipeg, Manitoba, Canada, Scientific Presentation 
30. Co-Author, Prospective Evaluation of Neck and Shoulder Function After unilateral neck Dissection, 
69th CSOHNS Annual Meeting, Presenters: H. Low, M. Ehsan, T. Overend, B. Chesworth, D. MacNeil, 
A. Nichols, J. Yoo, K. Fung, 2015 Jun 7, Manitoba, Canada, Scientific Presentation 
31. Presenter, The Control of Anaplastic Thyroid Carcinoma Cell Lines by Oncolytic Poxviruses, 
Presenters: N. Mundi, A. Nichols, S. Um, J. Barrett, G. Rizzo, M. Black, D. MacNeil, K. Fung, J. Yoo, J. 
Koropatnick, J. Mymryk, 2014, Ontario, Canada, Scientific Presentation 
32. Presenter, The Impact of Standardized Pre-Printed Order Sets on Post-Laryngectomy Physician 
Orders, Presenters: S. Ansari, L. Sowerby, J. Yoo, D. MacNeil, J. Franklin, A. Nichols, K. Fung, 2014, 
Ontario, Canada, Scientific Presentation 
33. Presenter, Targeting PIK3CA in Head and Neck Cancers with BYL719, An Alpha Specific PI3K 
Inhibitor, Presenters: G. Rizzo, A. Nichols, M. Black, J. Barrett, J. Yoo, K. Fung, D. MacNeil, 2014, 
Ontario, Canada, Scientific Presentation 
34. Presenter, Infraclavicular Free and Pedicled Flaps - A Novel Flap With Broad Applications in Head 
and Neck Surgery, Presenters: D. Angel, J. Yoo, K. Fung, D. MacNeil, A. Nichols, 2014, Ontario, 
Canada, Scientific Presentation 
35. Presenter, Vestibular Evoked Myogenic Potential (VEMP) Abnormalities in Patients with Visual 
Vestibular Mismatch. Canadian Society of Otolaryngology Annual Meeting. Halifax, NS. Presenters: 
MacNeil SD, Mallinson A, Galo J, Longridge N. 2009 May 
36. Presenter, The reliability of the reflux finding score among general Otolaryngologists. Canadian 
Society of Otolaryngology Annual Meeting. Jasper, AB. Presenters: MacNeil SD, Morrison M, Lee PK. 
2008 Jun 
37. Presenter, Diagnosis of Upper Aerodigestive Foreign Bodies: A Major Gap in Medical School 




38. Presenter, Disclosure of research results: demonstrating greater respect for research participants. 
Dalhousie University Medical School Summer Research Seminar Series. Halifax, NS. Presenters: 
MacNeil SD, Fernandez CV. 2005 Jun 
39. Presenter, Informing Research Participants of Research Results: An Analysis of the Attitudes of 
Canadian University-based Research Ethics Board Chairs. Canadian Pediatrics Society 82nd Annual 
Conference. Vancouver, BC. Presenters: MacNeil SD, Fernandez CV. 2005 
40. Presenter, The Development of Tilapia (Oreochromis niloticus) Chimeras and Short-term Culture of 
Undifferentiated Embryo Cells. Aquanet II Conference. Moncton, NB. Presenters: MacNeil SD, 
Pohajdak B, Wright JR. 2002 Sep 
41. Presenter, The development of tilapia germ-line chimeras from embryonic stem cell cultures. 
Department of Pathology Research Seminar, Dalhousie University, Halifax, NS. Presenters: MacNeil 
SD, Lu X, Pohajdak B, Wright JR. 2001 Apr 
International 
1. Co-Author, Early mortality with immune checkpoint inhibitors (IOs) in solid tumors: an inconvenient 
truth? 2018 ASCO Annual Meeting, Presenters: E. Winquist, D. MacNeil, 2018 Jun 1, Toronto, 
Ontario, Canada, Scientific Presentation 
2. Presenter, Does Parathyroidectomy Reverse Mortality Risk in Patients with Primary 
Hyperparathyroidism? A Systematic review and Meta-Analysis. International Conference on Head 
and Neck Cancer, 2016 Jul 1 
3. Presenter, Treatment of Early Stage Supraglottic Squamous Cell Carcinoma: Meta-Analysis 
Comparing Primary Surgery Versus Primary Radiotherapy. International Conference on Head and 
Neck Cancer, 2016 Jul 1 
4. Co-Author, Infraclavicular Pedicled  Adipofascial Flap for  Recontouring the Neck following Neck 
Dissection, ASOHNS ASM2016, Presenters: Tsu-Hui (Hubert) Low1 
Samantha Tam2, Allison Partridge2, Kevin Fung2, Anthony Nichols2, Danielle MacNeil2, and John 
Yoo2, 2016 Mar 6, Melbourne, Australia, Scientific Presentation 
5. Co-Author, A surgical algorithm for management of retrosternal goitre Expanding role of video-
assisted thoracoscopic surgery, ASOHNS ASM2016, Presenters: Tsu-Hui (Hubert) Low1 
Kevin Fung2, Anthony Nichols2, Danielle MacNeil2, Richard Inculat3, and John Yoo2, 2016 Mar 6, 
Melbourne, Australia, Scientific Presentation 
6. Co-Author, Shoulder Function after Scapular Free Flap, ASOHNS ASM2016, Presenters: Tsu-Hui 
(Hubert) Low1 
Allison Partridge2, Krupal Patel2, Kevin Fung2, Anthony Nichols2, Danielle MacNeil2, and John Yoo2, 




7. Presenter, Informing Research Participants of Research Results: An Analysis of Pediatric Informed 
Consent Conference in Randomized Controlled Trials. American Society of Hematology. San Diego, 





1. Co-Author, NSD1 is a Biomarker of Survival in HPV-Negative Head and Neck Squamous Cell 
Carcinoma, Canadian Society of Otolaryngology, Presenters: Ghasemi F, Prokopec S, MacNeil D, 





1. Presenter, The Development of a Head and Neck Cancer Survivorship Care Program: Practical 
Applications Within Existing Resources, Canadian Society of Otolaryngology, Presenters: O’Connell 
D, Arsenault M, Nayer S, Roth K, MacNeil D, 2019 Jun 3, Scientific Presentation 
2. Facilitator, Mentorship in Otolaryngology-Head and Neck Surgery: Improving Ourselves and Our 
Colleagues, Presenters: MacNeil D, Seikaly H, Gowrishankar M, Chan Y. 2019 Jun 2, Scientific 
Presentation 
3. Facilitator, Asymptomatic Primary Hyperparathyroidism: An Update on Surgical Indications and 
Surgical Advances, 71st CSOHNS Annual Meeting, Presenters: Dr. John Yoo, Dr. Jeffrey Harris, Dr. 
Paul Kerr, 2017 Jun 13, Saskatchewan, Canada, Scientific Presentation 
4. Facilitator, How to Produce High Quality Clinical Research Using Canadian Health Administrative 
Databases, 71st CSOHNS Annual Meeting, Presenters: Dr. Jason Beyea, Dr. Antoine Eskander, Dr. 
Steve Hall, 2017 Jun 13, Saskatchewan, Canada, Scientific Presentation 
5. Panelist, Beavertail modification of the Radial Forearm Free Flap: Indications. Technique and 
Functional Outcomes, 69th CSOHNS Annual Meeting, Presenters: E. Fung, J. Tibbo, D. MacNeil, K. 
Richardson, J. Harris, H. Seikaly, 2015 Jun 7, Manitoba, Canada, Scientific Presentation 
6. Panelist, Using Electronic Data for Research in Otolaryngology- Head and Neck Surgery, 69th 
CSOHNS Annual Meeting, Presenters: S. Hall, A. Eskander, K. MacDonald, D. MacNeil, 2015 Jun 7, 






Continuing Medical Education 
Courses 
Instructor - CME Course 
2017 Sep 16 C-Star, 6th Annual Emergencies in Otolaryngology Head & Neck Surgery 
Boot Camp 2017, Total Hours: 7 
Organizer - CME course 
2019 Nov 29 Lamplighter Best Western, LRCP Head and Neck Disease Site Team Annual 
Retreat, Total Hours: 4 
2019 Mar 5 LRCP, LRCP Head and Neck Cancer Survivorship Retreat, Total Hours: 3 
Presenter - Faculty Development Course / Workshop 
2015 Jun 9 Winnipeg, Patterns of Failure in Laryngeal Cancer- Glottis vs Supraglottic, 
Total Hours: 1 
2015 Jun 8 Winnipeg, Highly Effective Agents Identified in Genetically Characterized 
Anaplastic Thyroid Cancer Cell Lines, Total Hours: 1 
2015 Jun 8 Winnipeg, Head and Neck Surgery 2 continued, Total Hours: 1 
2015 Jun 8 Winnipeg, Frequence of HPV16 Prevalence and PIK3CA Hot Spot Mutations 
in Early-stage Laryngeal Squamous Cell Carcinoma, Total Hours: 1 
2015 Jun 7 Winnipeg, Beavertail Modification of the Radical Forearm Free Flap: 
Indications, Technique and Functional Outcomes, Total Hours: 1 
2015 Jun 7 Winnipeg, Using Electronic Data for Research in Otolaryngology-Head and 
Neck Surgery, Total Hours: 1 
2015 Jun 7 Winnipeg, Targeted Therapeutics: Optimization of a PIK3CA Mutational 
Analysis Pathway, Total Hours: 1 
Presenter - Grand Rounds 
2016 Oct 16 Head and neck, Krupal Patel, Total Hours: 1 
2013 Mar Anaplastic Thyroid Cancer Guidelines, Total Hours: 1 
2010 Mar - present Treating the difficult unexplained chronic cough. Total Hours: 1 
2010 Jan - present What is the impact of fellowship on residency education? Total Hours: 1 
2008 Oct - present Vestibular Evoked Myogenic Potentials. Total Hours: 1 
2007 Dec - present Dermoid cysts of the floor of the mouth. Total Hours: 1 
Lecturer- Workshop 
2015 Jun 7 Winnipeg, Using Electronic Data for Research in Otolaryngology-Head and 







Examiner- Graduate Student Theses 
2016 Dec 6 Title: A Longitudinal Study to Investigate Changes in Functional Ability and 
Concerns in Head Neck Cancer Patients Undergoing Neck Dissection 
 
PhD Convocation Title:  
 
Program: Health and Rehabilitation Sciences 
 








2016 - 2017 Shayan Kassirian, Supervisor, Schulich School of Medicine & Dentistry, 
Otolaryngology - Head & Neck Surgery 
2015 - 2017 Thomas So, Supervisor, Schulich School of Medicine & Dentistry, Otolaryngology - 
Head & Neck Surgery 
2015 - 2017 Jonathan Athayde, Supervisor, Schulich School of Medicine & Dentistry, 
Otolaryngology - Head & Neck Surgery 
2014 Ronghbo Zhu, Supervisor, Schulich School of Medicine & Dentistry, Otolaryngology - 
Head & Neck Surgery 
2014 Rochelle Johnstone, Supervisor, Schulich School of Medicine & Dentistry, 
Otolaryngology - Head & Neck Surgery 
Research Assistant 
2017 - present Shannan Hamel, Supervisor, Schulich School of Medicine & Dentistry, Otolaryngology 






Other Noteworthy Activities 
1995 Grade 9 Royal Conservatory of Music, Canada 
 
